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SUMMARY
Hormone Production by the Human Ovary
Sensitive, specific, precise and accurate radioimmunoassays have 
been developed for A, DHT, and T. These assays were applied to 
determine the profiles of these hormones in daily samples from normally 
menstruating women. Plasma samples were also obtained at hysterec­
tomy from peripheral and ovarian veins; where practical samples were 
obtained from the veins draining both the active and the contralateral 
ovaries. In this study a larger number of such samples had been 
obtained than has been reported previously and in addition the stage of 
the menstrual cycle was better documented than in previous reports by 
using as many parameters as possible -  menstrual history, ovarian and 
endometrial histology, and peripheral hormone levels.
Samples were obtained from 40 patients, of reproductive age, 
whose conditions did not affect ovarian function and in whom the stage 
of the menstrual cycle could be accurately assessed. Samples were also 
obtained from a number of patients with disorders which would affect 
their reproductive cycles. From the 40 patients with normal ovarian 
function a composite menstrual cycle was constructed. Using the newly 
developed radioimmunoassays and pre-established methods the levels 
of FSH, LH, PRL, P 170HP, OE^, A, DHT and T were determined in 
all plasma samples.
The hormone assays demonstrated that;-
(i) the peripheral levels from the"normally cycling” patients were 
within the normal ranges obtained from volunteers.
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(ii) the Graafian Follicles produced P, 170HP,A, DHT, T, and 
OE^. The amount of these compounds produced varied with the stage 
of development of the Graafian Follicles.
(iii) the corpus luteum also produced all of the hormones which folli­
cles produced [ c.f. (ii) above ]. The total production of steroid 
hormones was greatest during the MS stage of the cycle.
(iv) at certain stages of the cycle particularly the MS the contralateral 
ovary also produced small but significant quantities of hormones -  A, 
DHT, T and OE^.
(v) In the pathological and unphysiological conditions examined the 
ovarian production of hormones was unpredictable but allowed an 
insight into ovarian function in such patients.
On the basis of these results conclusions were drawn, as to the 
production of hormones by the human ovary, and the contributions 
made to this by the different ovarian structures, throughout the 
menstrual cycle.
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INTRODUCTION
Steroid Biosynthetic Pathways
The two primary functions of the human ovary are considered to 
be the production of mature ova and the secretion of hormones. The 
hormones which are secreted by the ovaries are steroid hormones. The 
biosynthetic pathways to these hormones which are active in the human 
ovary appear to be the same pathways by which steroid hormones are 
synthesised in other steroid producing glands. Evidence suggests that 
both the pathway and the pathway to steroid hormones (Dorfman 
and Unger 1965 ) are functional (Figures 1.1, and 1.2) in the human 
ovary (Coutts 1976). These biosynthetic pathways involve the condensa­
tion of 15 molecules of acetyl Co A and cyclisation of the condensation 
product to produce squalene which is then converted to lanosterol (C.30) 
which in turn loses 3. molecules of carbon dioxide to give rise to choles­
terol (C.27) which is the basic precursor of all steroid hormones. The 
cholesterol side chain is cleaved, iso-caprioc acid is removed and the A  ^
3B hydroxy steroid pregnenolone (C.21) is formed. Until this point the 
biogenesis is common to both A"^  and A  ^ pathways. In the A  ^ pathway 
(Figure 1.2) pregnenolone is sequentially converted to 17a hydroxypreg- 
nenolone (C.21) and dehydroisoandrosterone (C. 19). Any of these A  ^
steroids may be converted into the A'  ^ 3 oxo equivalent and enter the A^ 
pathway (Figure 1.1). In the latter pregnenolone is coverted to pro­
gesterone (A"^  3 0X0 C.21; P) which is 17a hydroxylated and then 
converted to androstenedione (C. 19;A). Where the A  ^ persists as far as 
dehydroisoandrosterone, this compound is converted to A. Thereafter 
the two pathways are again common with androstenedione being inter­
convertible with its 1713 reduced isomer, testosterone (T) and these C. 19
26
compounds being converted following oxidative attack at C. 19, to C. 18 
oestrogens-oestrone (OEj) being the product when A is the substrate and 
oestradiol (OE^) where the substrate, is T.
Steroidogenesis by the Ovary
The major biologically active hormones secreted by the ovary are 
P, the luteal hormone, and oestrogens, in particular OE^. Since the 
biosynthetic pathways described above are active in the ovary the organ 
must have the capacity not only to synthesise these hormones but also 
all of the intermediates on the pathways. Many of these intermediates 
are important biological hormones in their own right and the rates of 
synthesis and interconversion of them is of paramount importance to the 
functional activity of the ovary.
The ovary is a complex organ containing a number of potential 
hormone secreting tissues including the Graafian follicle, the corpus 
luteum and the ovarian stroma or interstitial tissue. Initially secretory 
roles were assigned to different cell types at different stages of the 
menstrual cycle as a result of histological and histochemical examina­
tions (Deane, Lob el and Romney 1962; Govan 1968). On the basis of 
these criteria it was concluded that during the follicular phase theca cells 
secreted steroids whilst granulosa cells acquired steroid synthesising 
characteristics just prior to ovulation (see Guraya 1971 for review). 
These initial histochemical studies have been complicated by in vitro 
biochemical studies. The original biochemical hypothesis, that oestro­
gens were produced by ovarian follicles, derived from the elegant animal 
experiments of Falck (1959) who showed that thecal cells and granulosa 
cells together caused vaginal cornification whilst granulosa cells alone 
did not. Short (1962) proposed a ‘two cell type’ theory of ovarian
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steroid production during the cycle; the theca interna cells secreting 
oestrogen during the follicular phase whilst the other cell type, probably 
luteinised granulosa cells, produced P during the luteal phase. From in 
vitro incubations with cell preparations Ryan and his colleagues con­
cluded that in the theca cells the pathway functioned producing OE^ 
whilst the granulosa cells synthesised P and other steroids via the A'^  
pathway (Ryan and Petro 1966; Ryan, Petro and Kaiser 1968). Synthe­
sis of steroids by human corpora lutea was demonstrated by in vitro 
incubation studies largely performed by Savard and his colleagues 
(Hammerstein, Rice and Savard 1964; Savard, Marsh and Rice 1965). 
These authors showed synthesis by human corpora lutea, from acetate, 
of a number of steroids including P, 17a hydroxyprogesterone (170HP), 
A, OE^ and OEj. This same group of workers (Rice and Savard 1966) 
and Lanthier and his colleagues (Patwardhan and Lanthier 1969; 
Somma, Sandor and Lanthier 1969) also showed the ability of the 
ovarian stroma to synthesise steroids, in particular androgens.
Ovarian Steroid Production
Attempts to confirm the secretion of these hormones by the ovary 
in vivo in the human have largely involved determination of the levels of 
these hormones in biological fluids. Prior to 1960 the fluid used was, of 
necessity, urine, since sensitive methods were not available for assay of 
the small levels of these hormones present in the plasma. The problems 
of extrapolation of the urinary metabolites to the active hormones made 
interpretation of such data difficult.
Since 1961 a number of methods have been described to measure 
submicrograms quantities of steroids in the peripheral plasma of females. 
The methods have included chronologically spectrophotometry, fluori-
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metry, double isotope derivative techniques, gas liquid chromatography 
with hydrogen flame and/or electron capture detectors and finally satura­
tion analyses -  initially competitive protein binding assays and currently 
radioimmunoassay. The advent of radioimmunoassay, which allows the 
measurement of steroids in the pi cogram range has opened many doors 
for the determination of hormone levels in normal women and in 
women with apparently deficient ovarian function. As a result, a great 
deal of data has been accumulated from a number of laboratories 
describing the levels of hormones in peripheral plasma samples in 
women throughout the normal menstrual cycle.
Hormone Levels during the Menstrual Cycle
The biosynthetic activities of the ovaries cannot be isolated from 
their inter-relationships with other endocrine glands since activity of the 
ovary at any point in time is a direct consequence of the external stimuli 
it is receiving. The functioning of the normal menstrual cycle depends 
upon complex inter-relationships between the ovary, the hypothalamus 
and the anterior pituitary. Figure 1.3 shows a schematic diagram of 
these inter-relationships which include negative feedback effects of OE^ 
and P on both the hypothalamus and the anterior pituitary; short-loop 
negative feedback effects of pituitary gonadotrophins on the hypothala­
mus; ultra-short-loop negative feedback effects of LHRH on the hypot­
halamus and the exceptional positive feedback effect of OE.^, on the 
hypothalamus or pituitary.
Data has been published previously from the Department of 
Obstetrics and Gynaecology showing the profiles of LH, FSH, OE^, 
170HP and P in the peripheral plasma of normally menstruating 
women (Coutts 1976). Figures 1.4 -  1.8 depict the mean ±  ISD (n =
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12) for FSH, LH, OE^, 170HP and P respectively in daily plasma 
samples throughout the normal menstrual cycle. To allow comparison 
of cycles of different length, all samples are plotted relative to the day of 
the LH peak which is designated day 0. Figure 1.9 depicts the mean 
values for all 5 of these hormones in the normal menstrual cycle. These 
levels of hormones in the normal cycle are similar to those published 
from other laboratories (Ross et al 1970; Mishell et al 1971; Abraham et 
al 1972; Shaaban and Klopper 1973). The basic sequence of events 
occurring in the normal cycle can be understood by reference to Figures 
1.4-1.9. When the corpus luteum regresses the negative feedback inhibi­
tion of OE^ and P is removed. Gonadotrophin releasing hormone is 
secreted and stimulates the pituitary release of FSH and LH. The 
peripheral levels of these gonadotrophins rise prior to and during menses 
(particularly FSH Figure 1.4). This FSH causes follicular development 
and production of OE^ which reasserts the negative feedback inhibition 
on gonadotrophin release. One follicle which has bound FSH within it 
(McNatty et al 1975) continues to grow whilst in the other growing fol­
licles the growth is arrested and they become atretic. The rising plasma 
level of OE^ (Figure 1.6) eventually causes a positive feedback effect 
which produces the mid-cycle surge of LH (Figure 1.5). This LH causes 
lutéinisation of the follicle and ovulation. Lutéinisation begins prior to 
the LH peak in response to the initial rise in LH levels (see 170HP 
levels Figure 1.7). Following ovulation the ruptured follicle develops 
into a corpus luteum which in the human secretes increasing amounts of 
steroid hormones including P (Figure 1.8), 170HP (Figure 1.7) and OE^ 
(Figure 1.6). The combined effects of OE^ and P reimpose the negative 
feedback preventing gonadotrophin release until luteal regression causes 
a reduction in these steroids, menses occurs and the next cycle begins.
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Ovarian Secretion of Hormones
Although the levels of steroid hormones in peripheral plasma 
have been of great value in understanding the events which occur in the 
normal human menstrual cycle and are of particular diagnostic value in 
certain cases of abnormal ovarian/hypothalamic/pituitary functions, they 
are not of great value in assessing the actual secretion of the hormones 
by the ovaries. Since most of the ovarian hormones are also synthesised 
by the adrenals it is impossible from peripheral plasma samples alone to 
determine ovarian secretion.
The ovaries are unlike other paired organs in the body in that 
usually only one of them is active whilst the contralateral ovary,
although not inactive, may be described as quiescent and does not in
that cycle produce a mature ovum.
Assessment of ovarian secretion of hormones can only be
achieved by sampling the blood draining the ovary and in this situation 
both the active and the contralateral ovarian veins can be sam­
pled. The limitations of the human as an experimental animal have 
resulted in only very few studies being performed in which levels of 
hormones have been determined in ovarian venous plasmas (e.g. Mikhail 
1970).
Since initiation of the studies presented in this thesis, a few papers 
have been published giving levels of some hormones in small numbers of 
samples of ovarian veins (de Jong, Van der Molen and Baird 1974; 
Calabresi et al 1976; McNatty et al 1976; Guerrero et al 1976; Dell’ 
Acqua et al 1976; Serio et al 1976; Kirschner, Zucker and Jespersen 
1976).
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Due to the inaccessibility of ovarian venous effluent except at the 
time of operation, when normal function might be disturbed by compli­
cating factors such as stress or anaesthesia, determinations of secretion 
and production rates of ovarian hormones is difficult. However, a few 
such studies have been performed (Baird and Fraser 1974) and where 
hormone levels in ovarian venous plasma are determined, assessment of 
peripheral levels simultaneously can allow comparison with normal 
menstrual cycle samples obtained in the absence of such complications.
In recent years, guided ovarian vein catheterisation technique has 
enabled selected ovarian vein effluents to be sampled at will, with the 
subjects being in a state approximating normal physiological condition 
(Jacobs 1969; Kirschner and Jacobs 1971).
Aims of the Study
The aims of the study presented in this thesis were to assess the 
ovarian production of a number of hormones. As described previously, 
in addition to the hormones described in Figures 1.6 to 1.8 the ovary 
also secretes androgens. According to in vitro studies both A and T 
have been implicated and 5a dihydrotestosterone (DHT) has been shown 
to be an intracellular effector of T action (Baulieu 1973). Although 
peripheral plasma levels of these C. 19 androgens had been published 
from other laboratories it was felt that the levels of A, T and DHT 
should be measured in normal cycle samples to compare these levels 
with published data and with peripheral levels in patients providing 
ovarian venous samples. Recently, prolactin (PRL) has been shown to be 
involved in the processes of the normal human menstrual cycle 
(McNatty et al 1975; Rolland et al 1976; Vekemans et al 1977) and in 
addition to the other hormones, the levels of PRL in peripheral
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plasmas throughout the menstrual cycle and in ovarian venous samples 
were assessed.
The aims of the study presented in this thesis were -
(1) To develop specific, sensitive, precise and accurate radioimmunoas­
says for A, DHT and T.
(2) Using these assays to establish the profiles of each of these C. 19 
androgens in daily peripheral plasma samples throughout the menstrual 
cycle.
(3) To obtain blood samples from patients undergoing surgery for 
conditions which did hot affect their reproductive function -  peripheral 
and bilateral ovarian venous samples where possible.
(4) To determine in these patients which is the active ovary and to use 
all available material to assess the stage of the cycle.
(5) To obtain samples from peripheral and ovarian veins in patients 
undergoing surgery who do not have normal reproductive function e.g. 
post-menopausal patients, patients on oral contraceptives, patients with 
polycystic ovarian disease etc.
(6) To sample in the same patients (5 above) where present, ovarian 
cyst, luteal and follicular fluids.
(7) To assess in the samples from (3), (5) and (6), above the levels of A, 
DHT and T and using methods already available, LH, FSH, PRL, OE^,
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170HP and P.
(8) To use the data obtained in the above to attempt to assess the 
ovarian secretion of the steroid hormones studied and where possible the 
ovarian structures responsible for steroid synthesis.
Figure 1.1
Biosynthetic pathways to steroid horm ones-  
the pathway.
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Figure 1.3
Schematic diagram showing the inter-relationships 
between the ovaries, the pituitary and the hypothalamus 
( “  represents negative feedback and + positive feedback. )
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Figure 1.9
Composite graph of mean levels of 
FSH, LH, OE2 , P and 170HP during the 
normal human menstrual cycle.
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MATERIALS AND METHODS
MATERIALS
Solvents
Ail solvents used were either ‘Analar’ grade obtained from BDH 
Limited, or ‘Pronalys’ grade purchased from May and Baker Limited. 
Where solvents were distilled, a 60 cm Vigreux Column was used 
(Quickfit Limited); the first and last 100 ml of each distillation being 
discarded.
Diethyl ether (BDH Limited), ethyl acetate (BDH Limited) and 
methanol (BDH Limited) were each distilled twice prior to use. Diethyl 
ether and both benzene (BDH Limited), and 2,2,4 trimethyl pentane 
(iso-octane) (BDH Limited), which were redistilled once, required to be 
distilled within 24 hours of use. Hexane (boiling point 67 -  70"; May 
and Baker Limited) and all other solvents were used as supplied by the 
manufacturers without purification.
Water used for rinsing glassware and to make up solutions for 
radioimmunoassay was de-ionised (Permutit Company Mark II portable 
de-ioniser) and then distilled in an all glass still (Quickfit from Jobling 
Limited).
Chemicals
Where possible ‘Analar’ grade chemicals were employed. Di­
sodium hydrogen phosphate (anhydrous), sodium dihydrogenortho- 
phosphate and gelatin were obtained from BDH Limited and dextran
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T70 from Pharmacia Fine Chemicals, Uppsala, Sweden. Charcoal 
(Norit NK) from Hopkins and Williams Limited was washed twice with 
methanol, the ‘fines’ being decanted each time, and dried thoroughly 
before use. Thimerosal, which was used as an antibacterial agent 
(0.01%), was obtained from Sigma Limited (London).
Steroids
Progesterone, 170HP, T, A and DHT were purchased from Ster- 
aloids Limited. Oestradiol was purchased from Koch-Light Laboratories 
Limited.
These steroids were purified by paper chromatography and recrys­
tallised prior to use as standards for radioimmunoassay. Stock solutions 
of these steroids (1 mg/ml) were prepared in methanol and stored at 4". 
Solutions of the concentration required for radioimmunoassay were 
prepared by dilution of these stock solutions.
Other authentic steroids which were used in cross reaction studies 
were generous gifts from Dr. Kirk of the MRC Steroid Reference Collec­
tion.
Radioactive Steroids
Progesterone-[1,2-H3(N)] (33.5Ci/mmol), 170H P- [1,2-H3(N)] 
(49.2Ci/mmol), T-[1,2-H3(N)] (42.3Ci/mmol), DHT-[1,2,4,5,6,7-H3]
(80Ci/mmol) and A [1,2-H^] (40Ci/mmol), were purchased from New 
England Nuclear Corporation (Frankfurt, Germany).
Oestradiol-17B-[6,7-H3] (40Ci/mmoI) and D H T -[4“'C](50mCi/- 
mmol) were purchased from the Radiochemical Centre (Amersham).
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All radioactive steroids were stored in solutions, in methanol or 
methanol/benzene mixtures (100ml) at 4". The purity of these standards 
was checked by paper chromatography on receipt from the manufactur­
ers and at approximately 2 monthly intervals whilst in use.
Solutions for Radioimmunoassay
Phosphate Buffer Solutions
61.0ml O.IM disodium hydrogen phosphate solution were 
thoroughly mixed with 39.0ml of sodium dihydrogen phosphate. An 
equal volume of this mixture when mixed with double distilled water 
gave 0.05M phoshate buffer solution of pH 7.0.
The pH was checked with a pH meter (E.I.L. Limited) prior to 
using this buffer solution to prepare reagents required for the radioim­
munoassays.
Gelatin Solutions
0.1% gelatin solution was prepared by dissolving lOOmg gelatin 
and 0.01 mg thimerosal per 100ml of 0.05M phosphate buffer pH 7.0.
Dextran Coated Charcoal (DCC)
Dextran coated charcoal solutions were prepared by dissolving the 
required amount of charcoal, dextran T70 and gelatin in 0.05M phos­
phate buffer pH 7.0. The recipes for the DCC used in the individual 
assays are described under the methodological section for each assay.
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Tritiated Steroid Solutions
Tritiated solutions of steroids which were used for radioimmun­
oassay were prepared by diluting the stock tritium labelled material to 
the desired concentration with 0.1% gelatin solution. The concentra­
tions were adjusted to give the radioactivity described in the individual 
methods in 0.1ml of solution.
Antisera Solutions
Each antiserum was diluted to 1/100 with 0.1% gelatin solution 
and aliquots were stored at -20" until required. A fresh aliquot was 
diluted to the working dilution of the antiserum in 0.1% gelatin on the 
day of use.
Equipment
The following pieces of apparatus were used routinely in radioim­
munoassays.
Whirlymixer
For the purposes of ensuring even mixing of the reagents in the 
tubes, each was placed on the whirlymixer (Fisons Scientific Apparatus 
Limited) and vortexed for a period of 4 seconds.
Magnetic Stirrer
A magnetic stirrer (Toyo, supplied by Chem Lab Instruments 
Limited) was used to stir solutions required for the radioimmunoassay to 
ensure homogeneity, particularly of the DCC suspension.
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Repettes
A 10.0 ml repette (Jencons Limited) was used to deliver repetitive 
amounts of 1 ml DCC suspension.
Hamilton Syringes
For dispensing repetitive amounts of 10, 20, 100 and 200 ul 
Hamilton Gas Tight Syringes (V.A. Howe Limited) with repeating 
dispenser attachments (P.B. 600: P.B. 600-10) were used.
Oxford Samplers
Precise and reproducible sampling of plasmas was performed 
using mono-range Oxford samplers (Oxford Laboratories Limited; 
supplied by Boehringer Limited, London) with inert disposable, non­
wetting fluoroplastic tips.
Vacuum Oven
Solvents were evaporated from extracts in a vacuum oven 
(Qualivac, LTE Limited from G.D. Searle and Company) at -24  inches 
of mercury and a temperature less than 40".
Centrifuge
The free steroid fractions bound to DCC were spun down by 
centrifugation in a refrigerated centrifuge (MSE 6L with multiplace head) 
at 4° and 1,500 g.
Glassware
All tubes used for radioimmunoassay were used as disposable and 
discarded after use. Tubes (Excelo Limited) were rinsed copiously
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before use with deionised distilled water, dried and washed with the 
extracting solvent.
Scintillation Counting
Samples for determination of radioactivity were counted at preset 
settings for in a Nuclear Chicago Isocap 300 Liquid Scintillation 
Spectrometer (G.D. Searle and Company) in 7ml of NE 250 liquid scin­
tillation fluid. This scintillation fluid was obtained commercially from 
Nuclear Enterprises Limited, Edinburgh. It is a dioxan based scintillator 
similar to Bray’s solution (Bray 1960). Using this scintillation fluid 
was counted in the aqueous samples from radioimmunoassays (1.2ml
0.05M phosphate buffer/7ml NE 250) with an efficiency of 34% and in 
the organic based samples from chromatography (0.25ml methanol/7mi 
NE 250) with an efficiency of 48%.
Scintillation Vials
Disposable polypropylene scintillation vials (Intertechnique 
Limited) were used in all cases. The scintillation fluid was placed in the 
vials and the aliquot for determination of radioactivity was added.
Blood Samples
Normal Cycle Samples
The determination of the levels of steroid and gonadotrophin 
hormones in the peripheral blood of normally menstruating volunteers 
presented a number of problems.
1. Definition of what is a ‘normal cycle’.
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2. Collection of all samples at the same time each day to ensure that 
any variability during the day did not complicate the results.
For the purposes of this study ‘normal cycles’ were defined as 
cycles which
a) had a luteal phase of at least 13 days (Rock, 1949; Van de Wiele 
and Turksoy, 1965) measured from the day of the maximum LH 
value until the onset of the following menses.
b) were obtained from subjects having no abnormalities or special 
peculiarities -  either medical or menstrual.
Ideally in addition to the above criteria for inclusion in the nor­
mal series, the subjects should be of proven fertility.
It was not possible, however, to obtain volunteers who fulfilled the 
last criterion.
Serial daily plasma samples were collected throughout 7 cycles 
from 5 volunteers. These women were healthy, aged 18 to 26 years, 
nulliparous and unmarried. The criteria therefore used initially in 
selecting appropriate subjects were:-
a) a history of regular menstrual cycles of between 27 and 32 days,
b) no general medical or gynaecological abnormality and
c) no history of taking exogenous source of a hormone preparation.
In hindsight these volunteers were all shown to have luteal phases of at 
least 13 days.
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Daily blood samples (10ml) were collected at 9.00 a.m. each 
morning from the antecubital veins into lithium heparin containers. 
Venesection was performed on alternate arms each day with the patient 
in a sedentary position. Plasmas were separated within 30 minutes by 
centrifugation on a bench centrifuge at 1500 r.p.m. Plasma aliquots 
were removed for protein hormones (LH, FSH and PRL) and the 
remainder of each plasma was stored at -20* until assay of the steroid 
hormones.
Ovarian Venous Samples
Informed consent was obtained from patients going for hysterec­
tomy, to allow samples of ovarian venous blood to be taken by vene­
puncture under direct vision, once the abdomen was opened. Before 
excising the supporting structure of the uterus, straight Rochers clamps 
were applied on either side of the uterine body in such a manner that 
the fallopian tube, the round ligament, the ligament of the ovary, and 
the broad ligament right down to just above the utero-cervical junction, 
were clamped, all in one piece. This ensured that subsequent filling of 
the veins in the pampinifoim plexuses could only have come from the 
ovary, because the utero-ovarian anastamoses had by now been ex­
cluded. The site of venepuncture for the ovarian venous sample was 
usually about 1 cm away from the hilus of the ovary, where the vessel 
begins to enter the infundibulo-pelvic ligament (see Figure 2.1).
Using a sterile 5 ml syringe with a 25 guage needle the blood was 
drawn very slowly, with intermittent pressure, each momentary pause 
allowing the venous cavity to be refilled by fresh ovarian effluent. This 
procedure was performed initially on the ovary which on visualisation 
appeared more active, and then repeated on the contralateral ovary. A
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sample of peripheral blood was simultaneously taken from the ante- 
cubital vein. The blood was then transferred into lithium heparin 
containers.
The blood samples were centrifuged at 1500 r.p.m. in a bench 
centrifuge for ten minutes and each supernatant plasma was transferred 
into a sterile container. Aliquots for protein hormone assay were 
removed and the remainder of the plasma was stored at -20* until 
processed further.
Figure 2.1
Posterior view of the right uterine adnexa (top) 
with its vascular network (bottom) on which 
is illustrated the site of venepuncture for 
ovarian venous sampling.
52
JFALLOPIAN TUBE
UTERUS
MESOVARIUM
OVARIAN
LIGAMENT
OVARY
INFUNDIBULOPELVIC
LIGAMENT
OVARIAN VEINS' OVARIAN ARTERY
COMMUNICATING
VEIN
S IT E  OF V EN E P U N C T U R E
53
METHODS
Dating of the stage of the menstrual cycle
A) Dating of the Endometrium according to Morphological Changes
The original observations of histological changes in the endo­
metrium by Hitchman and Adler (1908), elaborated by Schroeder (1915), 
Novak (1915), O’Leary (1929), Bartelmez (1938) and correlated with 
coincident changes in the ovary by Frankel (1909), Meyer (1920) and 
Noyes, Hertig and Rock (1950) established the sequence of proliferative 
(pre-ovulatory) and secretory (post-ovulatory) morphological phases. 
Development of the biopsy method greatly assisted the correlation of the 
histology of the endometrium with the stage of the cycle. The usefulness 
of dating the endometrium lies in the fact that it gives a rough idea of 
quantitative progesterone effect, and also indirectly of the time of ovula­
tion. Selye (1947) even goes further to say that ‘endometrial biopsy is a 
superior form of hormone assay because of its freedom from a multitude 
of technical uncertainties.’
Detennination of histological changes of the endometrium is 
based on a 28 day menstrual cycle with ovulation occurring on the 14th 
day. The cycle begins on the first day of menstruation. The menstrual 
phase is variable lasting on the average 4 days. From then until the 14th 
day is the proliferative phase and the two weeks following that the secre­
tory phase. Whilst it is generally accepted that ovulation does not 
always occur on the 14th day of the cycle and that the proliferative 
phase is of variable duration, there is a constant relationship in that 
ovulation occurs 14 days ±  2 before the onset of the next menstrual 
cycle.
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Morphological changes for dating the endometrium were evalu­
ated from the most advanced area in the histology slide that was 
chosen. This was to overcome the possible sources of error resulting 
from the fact that there must exist a time lag in the responses to the 
hormone by the different parts of the endometrium. Even while men­
strual breakdown is still taking place there is already regeneration of the 
endometrium in the adjacent portion,,in readiness for the next cycle.
Criteria used in dating of the endometrium histologically (Noyes, Hertig 
and Rock, 1950).
Early Proliferative Phase (days 4 - 7 )
The endometrium shows occasional glands left from the previous 
menstrual phase with its involutional changes (secretory exhaustion). 
The stroma is compact, spindle-shaped cells with anastamosing 
processes and relatively large nuclei undergoing mitosis are evident 
(Plate I). There is evidence of regenerating surface epithelium especially 
between glandular openings.
Mid Proliferative Phase (days 8 - 1 0 )
In this phase the glands begin to curve and elongate into the 
stroma which is oedematous and laden with ‘naked nucleus’ type cells 
still showing mitosis (Plate II). The glandular epithelium is commencing 
to show pseudostratification.
Late Proliferative Phase (days 1 1 - 1 4 )
The endometrial glands here are tortuous and show evidence of 
active growth (numerous mitotic nuclei). The stroma is again dense 
with cellular nuclei showing mitosis. The pseudostratification
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mentioned earlier in glandular epithelium has become more marked 
(Plate III). The surface epithelium is somewhat undulating.
Early Secretory Phase (days 15 -  20)
Following ovulation the progestational effect on the endometrium 
becomes evident and a more critical appraisal of the dating of the 
endometrium can be made. After a ‘silent period’ in the endometrial 
changes (36 hours following ovulation) very occasional subnuclear 
vacuoles may be seen in the glandular epithelium of what is essentially 
proliferative endometrium (day 16).
The pseudostratification of the glandular epithelium becomes 
more marked (day 17) and basal vacuolation more evident whilst the 
mitotic figures in glandular and stromal cells persist.
By day 18 of the cycle, the nuclei of the glandular epithelial cells 
begin to line up in the centre of the cells, with the homogenous cyto­
plasm above and vacuoles below them. The glands themselves are 
becoming increasingly tortuous. Mitosis in the glandular and stromal 
cells are only occasionally seen (Plate IV).
As the basal vacuoles begin to decrease the mid secretory phase is 
reached.
Mid Secretory Phase (days 21 -  24)
Very occasional subnuclear vacuoles are present by now with the 
nuclei of the glandular epithelium being mainly basal. Acidophilic 
secretions in the glandular lumen are clearly seen (Plate V).
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The stroma is maximal and oedematous with thin-walled spiral 
arteries in it (day 22). The prominence of spiral arteries and arterioles 
indicate a further development in the endometrium. Stromal cells begin 
to condense around the arterioles and acquire increasing amounts of 
cytoplasm. This is the earliest predecidual change detectable. The 
collection of predecidual cells round the arterioles become more marked; 
some still showing mitosis. The endometrium comes to the end of the 
mid secretory phase.
Late Secretory Phase (days 25 -  28)
On the commencement of the late secretory phase predecidual 
changes begin beneath the surface epithelium with still some stromal 
oedema existing except around the blood vessels. Lymophocytic infiltra­
tion begins to take place and soon this is associated with polymorphonu­
clear leucocytic infiltration indicating the prominence of predecidual 
changes. Focal necrosis of the decidua associated with haemorrhages
and clumping of the stromal cells indicates early menstruation. The tor­
tuous glands which, all through the secretory phase, have been secreting 
their acidophylic secretions into the glandular lumen are by now in a 
state of “secretory exhaustion” (Plate VI). The infiltration of polymor­
phonuclear leucocytes persists right through menstruation till day 3 or 4 
of the cycle.
Menstruation (days 1 -  3)
Varying degrees of sloughing of the endometrium with hae­
morrhages are evident with concommitant early regeneration of epithe­
lium starting usually near the ‘mouths’ of glandular tracts.
PLATE I
Histological preparation of human endometrium
in the EP phase.
PLATE II
Histological preparation of human endometrium
in the MP phase.
PLATE n i
Histological preparation of human endometrium
in the LP phase.
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PLATE IV
Histological preparation of human endometrium
in the ES phase.
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PLATE V
Histological preparation of human endometrium
in the MS phase.
PLATE VI
Histological preparation of human endometrium
in the LS phase.
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B) Dating of the stage of the menstrual cycle using other criteria.
1. Visualisation of the ovaries
On opening the abdomen the ovaries were visualised in detail for 
evidence of growing follicles (mid proliferative), large follicles with 
impending rupture (late proliferative), haemorrhages on the ovary (recent 
ovulation), corpora lutea (secretory phase) and ‘silent’ apparently 
inactive ovaries which might assist categorisation of it into one of the 
above mentioned stages. It must be pointed out that a negative finding 
macroscopically of the ovary was equally pertinent in assisting staging 
the phase of the menstrual cycle, especially in relation to other 
parameters.
2. Histological appearance of the ovary
Where ovaries were available for detailed histological study 
reports, on the serial sections performed, were obtained through the good 
offices of Dr. Lees, Senior Consultant Pathologist, Department of 
Pathology, Glasgow Royal Infirmary.
3. Menstrual History
The day of the cycle according to the date of the last menstrual 
period and the previous cyclical pattern of the patient, where available, 
were also used to categorise the patients in this study.
Extraction of Steroid Hormones from Plasma
Different volumes of plasma were required to be extracted for 
assay of the different hormones at different stages of the menstrual cycle 
and the following general scheme for extraction was employed.
The plasma (0.01 ml to 0.2ml diluted, where necessary, with 
deionised, distilled water to 0.05ml) was extracted with 3 mis of the
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extracting solvents by shaking for 20 minutes, either horizontally in B 14 
stoppered tubes (Jobling Limited) in an automatic shaker (W atson- 
Balgray Limited) or vertically in disposable tubes 16 x 100 mm (Excelo 
Limited) in a multivortex mixer (Baird and Tatlock Limited). After 
shaking, the tubes were allowed to stand for a few minutes to allow the 
two layers to separate and were then placed in a freezing mixture of solid 
carbon dioxide. After the lower aqueous phase had frozen the organic 
layers were decanted either into chromatography tubes or into assay 
tubes as required. The organic layers were then evaporated to dryness in 
the vacuum oven.
The extracting solvents used in the various assays were;-
OE^, 170HP, T and DHT — diethyl ether 
A — Hexane (boiling point 67°-70“)
P — petroleum ether (boiling point 40°-60°)/ethanol (15/1 v/v)
In the cases of T and DHT, assays which employed chromatogra­
phic purification of the extracts, small amounts of tritiated hormones 
were added to the plasma prior to extraction to monitor methodological 
losses during chromatography.
Determination of the Extraction Efficiency
The efficiency of the extraction was checked by adding 0.01ml 
methanol,containing the tritiated hormones to be extracted, to each of 20 
extraction tubes, evaporation of the solvent, addition of the appropriate 
volume of plasma from a mixed pool (dated plasmas obtained from the 
blood bank -  a mixture of male and female plasmas), gentle mixing at 
room temperature for Ih and then extraction as described above. After 
freezing, the supernatant organic layers were decanted directly into scin­
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tillation vials for radioactivity determination and percentage extraction 
for each was assessed by comparison with total vials prepared by adding 
to the scintillation fluid directly 0.01ml of methanol containing the 
hormone under test (H^ labelled) plus 3ml of the extracting solvent.
Celite 545
Celite 545 (John’s Man ville Limited) was washed prior to use for 
chromatography. 400 g of celite were suspended in a solution of 1.5 x 
10“^ M ethylenediaminotetra-acetic acid (E.D.T.A.) and the pH of the 
suspension was adjusted to between pH 2 and 3 by addition of conc. 
hydrochloric acid. An equal volume of distilled water was added and 
the mixture was heated at 70° for 45 minutes with constant stirring. 
After standing, the supernatant layer was decanted and the celite was 
washed with distilled water on a Buchner funnel until the washings were 
of neutral pH. The celite was further washed twice with methanol at 60° 
for 45 minutes with stirring and was then filtered on a large Buchner 
funnel under vacuum. The material remaining on the filter was washed 
sequentially with 500 ml each of iso-octane, benzene, hexane, dichlor- 
ethane and water -  the solvents which were to be employed later in 
celite partition chromatography. Finally, the celite was washed with 
acetone to remove any remaining traces of water, air-dried in an open 
tray for several hours in a fume cupboard and oven-dried at 200° for 48h 
. The celite was then ready for use in chromatography.
Preparation of Celite Containing Stationary Phase for 
Partition Chromatography
Washed celite was suspended in iso-octane (lOOg/litre w/v) and 
ethylene glycol (50ml/lOOg celite v/w) was added drop-wise over a 
period of approximately Ih with constant stirring. After all of the
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ethylene glycol had been added, the mixture was stirred for a futher Ih 
and the celite containing ethylene glycol as a stationary phase was now 
ready for use in chromatography columns.
Celite Partition Chromatography
Glass columns, 25 cm high and 0.75 cm in diameter, were used 
for celite partition chromatography. These columns were fitted with a 
tap to regulate flow rate and had a female B19 joint at the top to allow 
the fitting of a solvent reservoir (Figure 2.2). A plug of washed glass 
wool was placed in the column just above the tap and covered with a 
disc of fib reglass paper (0.75 cm in diameter) to prevent leakage of celite.
Washed celite 545 containing ethylene glycol (see above) was 
packed into these columns in iso-octane which was allowed to flow 
throughout the procedure thus preventing air bubbles collecting in the 
columns. The celite was packed under gravity ensuring that the solvent 
level was always above the top of the column. Columns were packed to 
a height of 19 cm, tightly enough to give a flow rate, when the tap was 
fully open, of 30 to 32 drops per minute.
For chromatographic separation of DHT and T using these 
prepared celite columns the following mixtures of solvents were 
employed:-
Solvent I -  benzene/iso-octane (5/95; v/v)
Solvent II -  benzene/iso-octane (40/60; v/v)
Before application of the samples the iso-octane in which the 
column had been prepared was replaced with solvent I, and a total of 
50mls were eluted through the column.
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Figure 2.2
Diagram of the column used for celite 
partition chromatography.
19 cm
Reservoir
Benzene : Iso-octane 
5 : 95
Celite 545
Diameter 0.75 cm
Fibre glass filter paper 
Glass wool
Collection Tube-
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Separation of Dihydrotestosterone and Testosterone 
from Plasma using Celite Partition Chromatography
Tritiated T (0.75nCi;5pg) and tritiated DHT (lnCi;4pg) were 
added in 0.02ml methanol to 0.2ml of plasma and mixed. The plasma 
was then extracted as described above. The dried ether extract was 
redissolved in 1ml of solvent I and transferred to the column using a 
Pasteur pipette. This transfer procedure was carried out a further two 
times using 1ml of the solvent each time, whilst the first ml of the 
solvent was percolating into the column. When the three transfers had 
penetrated into the column, a further 27ml were added to the reservoir. 
Bulk fractions of the eluate were collected as desired.
The first 5ml were discarded, and the 6th to the 25th ml inclusive 
were collected in a disposable tube, (DHT fraction). The remaining 5ml 
of solvent were also discarded. When the miniscus of solvent I was level 
with the top of the celite column 30ml of solvent 11 were added to the 
reservoir. The first 5ml of this (31st to 35th ml) were discarded. The 
36th to 50th ml inclusive (T fraction) were collected into a disposable 
tube and the remaining eluate was discarded. Figure 2.3 shows the 
profile obtained in such a separation. These columns were then eluted 
continuously with a further 50mls of solvent 1 and were ready for re-use.
Bulk fractions collected in disposable tubes were evaporated to 
dryness in the vacuum oven. Methanol (0.75ml) was added to each 
dried extract and the tube contents were dissolved by whirlymixing for 
10 seconds. An aliquot (0.25ml) was transferred from each tube to a 
scintillation vial for determination of radioactivity and hence computa­
tion of recoveries and two further aliquots of 0.25ml were transferred to
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assay tubes for radioimmunoassay (see Figure 2.4).
Each batch of 5 columns contained 3 unknown samples. I blank 
to determine any methodological interfering factors and I internal quality 
control plasma for assay validation.
Values obtained for DHT and T following chromatography and 
radioimmunoassay were corrected for individual recoveries to give 
absolute values.
Radioimmunoassay of Dihydrotestosterone and Testosterone
The antiserum Y 6 / 4 ,  which was raised to T-3-oxim e bovine 
serum albumin was used for radioimmunoassay of these C19 androgens. 
This antiserum was a generous gift from Dr. Brian Cook of the Depart­
ment of Steroid Biochemistry, Glasgow University.
Standard curves in triplicate of 0, 10, 20, 50, 100, 200, 300, and 
500pg were pipetted into assay tubes from a stock solution in methanol 
(Ing/ml of either DHT or T) and 0.25ml methanol was added and 
evaporated to dryness. This addition of methanol was to ensure that the 
standard curve was compatible with the unknown samples and to guard
against any possible interference due to methanol.
1. Dihydrotestosterone : The antiserum (O.lml; 1/6000 dilution) and 
[1, 2, 4, 5, 6, 7, (N) H^] DHT (7.2nCi; 25pg;0.1ml) in buffer were added 
to the standard tubes and the sample aliquots obtained as described 
previously following chromatography. The mixtures were incubated at 4° 
for Ih, and the free and antiserum bound steroid fractions were separat­
ed by addition of 1ml of DCC (200mg of charcoal, 25mg of d ext ran T70
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and lOOmg gelatin/100ml).
The tubes were allowed to stand at 4° for a further 20 minutes (see 
stripping curve in Results Section) and then centrifuged at 1,500 g for 20 
minutes at 4 \  The supernatant fractions were decanted directly into 7ml 
NE 250 scintillation fluid in disposable vials and the radioactive content 
of each was determined.
In addition to the unknown samples and the standard curve, tripli­
cate tubes which contained buffer in place of antiserum (no As tubes) 
and triplicate tubes to which were added buffer in place of charcoal (no 
C tubes) were processed with each assay. These tubes facilitated deter­
mination of the total amount of radioactivity added (no C tubes) and the 
non specific binding (no As. tubes).
A standard curve was constructed relating percentage radioactivity 
bound to the mass of DHT on a linear/log scale (Figure 2.5).
The percentage bound for unknown samples was calculated and the 
equivalent mass of DHT determined using the standard curve.
2. Testosterone : Antiserum (0 .1ml; 1/6000) and [1-2 (N) H^] T (5.8 
nCi;38pg;0.1ml) in phosphate buffer were added to each of the standard 
tubes (0-500pg) described previously, to the aliquots from chromato­
graphy and to triplicate of no C tube. Triplicate no As were also 
prepared. The mixtures were incubated at 4° for Ih. Free and antiserum 
bound fractions were separated following addition of 1ml of DCC to 
each tube using the same recipe as described for DHT assay. The tubes 
were allowed to stand at 4° for 10 minutes (see stripping curve in Results
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Section), then centrifuged,(l 500g;20 minutes), the supernatant bound 
fractions were decanted, the radioactive content of each determined and 
a standard curve constructed as described for DHT. A typical T standard 
curve is shown in Figure 2.6.
Tables 2.1 and 2.11 list the cross reactions obtained using Y6/4 
antiserum with a variety of authentic steroids, for DHT and T respec­
tively under the conditions employed in these assays.
Table 2 I
Table showing the cross reactions obtained 
using the antiserum Y6/4 to assay DHT
Steroids % cross reaction
DHT
T
A
Dehydroisoandrosterone
P
O F.
OE
170HP
Deoxycorticosterone
100
150
1.8
< 0.2
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Table 2 II
Table showing the cross reactions obtained 
using the antiserum Y6/4 to assay T
Steroids % cross reactions
T
DHT
A
Dehydroisoandrosterone
P
OE.
OE
170HP
Deoxycorticosterone
100.0
55.0
0.8
< 0.2
For the purpose of determination of percentage cross reaction for all 
assays described in this thesis, the formula used was that of Abraham 
(1974):-
% cross reaction =
Mass of hormone of interest causing 50% drop in binding
Mass of cross reacting substance causing 50% drop in binding
X 100
Figures 2.7 and 2.8 are flow sheets of the radioimmunoassays for DHT 
and T respectively.
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Radioimmunoassay of Androstenedione
Androstenedione levels in plasmas were determined by radioim­
munoassay using an antiserum raised to A-7-oxo-bovine serum 
albumin. The antiserum prepared using the technique described by 
Weinstein et al (1972) was purchased commercially from Miles-Yeda 
Limited. This antiserum was used for specific radioimmunoassay of A 
without chromatography.
The plasma (0.05ml or less diluted to 0.05ml with deionised 
distilled water) was extracted as described previously and the organic 
layers were decanted directly into assay tubes. A standard curve in 
triplicate of 0 to 500pg was pipetted into assay tubes from a Ing/ml 
stock solution in methanol and no As and no C tubes in triplicate were 
also prepared. [1-2 (N) H^] A, (6.3nCi; 40pg; 0.1ml) and antiserum 
(0.1ml) in buffer were added to each assay tube and the mixtures were 
incubated at 4“ for Ih. The free and antiserum bound fractions were 
separated following addition of 1ml DCC (recipe as described for DHT). 
After standing at 4° for 10 minutes (see stripping curve Chapter 3) the 
tubes were centrifuged, the supernatant antiserum bound fractions 
decanted as described for DHT and the radioactivity present in each was 
determined.
A typical standard curve for A and a flow sheet of the A radioim­
munoassay method are shown in Figures 2.9 and 2.10 respectively.
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Figure 2.4
Flow diagram of extraction and chromatographic 
separation used prior to radioimmunoassays of DHT and T.
PLASMA
Extract ~ 1 x 3 ml Diethyl Ether 
Drikold Freezing Mixture 
Decant
PLASMA EXTRACT
3 X 1 ml solvent 1.
CELITE CHROMATOGRAPHY
/
6 -  25 ml 
solvent 1
DHT
36 -  50 ml
solvent II
Vaccum Oven to dryness
V
Dissolve in 0.75 ml Methanol
0.25 ml
Recovery
2 X 0.25
Assay
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Figure 2.5
A typical standard curve for DHT radioimmunoassay.
% Bound
60
50
40
30
20
10
100 1000
DHT(pg)
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Figure 2.6
A typical standard curve forT  radioimmunoassay.
% Bound
60-
40 -
30-
2 0 -
10 100 1000
T(pg)
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Figure 2.7
Flow - diagram of DHT radioimmunoassay. 
PLASMA EXTRACT after chromatography
Evaporate solvent in vacuum oven
Add 0.1 ml (1 ,2 A 5 ,6 ,7 , (N )h3)D H T
(7.2 nCi and 25 pg)
Add 0.1 ml Y|- T - 3  oxime-Bovineserum A lbum in-antiserum
Mix
INCUBATION Ih , 4 °C, pH7.0
Add 1 ml DCC
(200 mg % charcoal, 100 mg % gelatin,
25 mg% Dextran T70)
After 20 minutes centrifuge at 4°C and 1500g
V
SUPERNATANT PRECIPITATE
(ANTISERUM BOUND FRACTION) (FREE STEROID FRACTION)
RADIOACTIVITY DETERM INATION
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Figure 2.8
Flow diagram of T radioimmunoassay.
PLASMA EXTRACT after chromatography
Evaporate solvent in vacuum oven 
Add 0.1 ml (1,2 (N) H^) (5.8 nCi, 38 pg)
Add 0.1 ml Y|- T -  3 -oxim e-B ovineserum  A lbum in-antiserum
Mix
\1/
INCUBATION Ih , 4 C, pH 7.0
Add 1 ml DCC
(200 mg % charcoal, 100 mg % gelatin,i 
25 mg % Dextran T70)
After 10 minutes centrifuge at 4°C and 1500 g
V
SUPERNATANT ^ PRECIPITATE
(ANTISERUM BOUND FRACTION) (FREE STROID FRACTION)
RADIOACTIVITY DETERM INATION
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Figure 2.9
A typical standard curve for A radioimmunoassay
% Bound
90
80
70
60
50
40
30
20
10
10 100 1000
A (pg)
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Figure 2.10
Flow diagram of A radioimmunoassay.
PLASMA
E x tra c t-1 x3 ml HEXANE (67"-70 l 
Drikold Freezing Mixture 
Decant
PLASMA EXTRACT
Evaporate solvent in vacuum oven 
Add 0.1 ml ( I -2 H^) A (6.3 nci, 40pg)
Add O.I ml A - 7-oxo-B ovineserum  Album in-A ntiscrum
Mix
INCUBATION 111, 4°c, pH 7.0
Add 1 ml DCC
(200 mg % charcoal, l_00 mg% gelatin, 
25 mg % Dextran T70)
After 10 minutes centrifugeyat. 4°C and 1500 g
UPERNATANT ^  PRECIPITATE 
(ANTISERUM BOUND FRACTION) (FREE STEROID FRACTION)
r a d i o a c h v h  y  d e t e r m i n a t i o n
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RESULTS
1. Extraction of Steroids from Plasma
The efficiency of the extraction procedures employed prior to 
steroid radioimmunoassay was checked using tritium labelled hormones 
as described in Chapter 2, Table 3.1 lists the mean percentage extraction 
plus the standard deviations for A, T, DHT, P, 170HP and OE^. The 
extractions of OE^, 170HP and P were taken from these figures as being 
quantitative and no corrections were applied.
Table 3.1
Mean % extractions (±SD ) of steroid hormones from plasma
STËROID Mean % Extraction'*' S.D
A 80.0 ±1.2
DHT 97.2 ±5.1
T 92.0 ±  6.1
P 96.6 ± 5 .7
170HP 99.7 ± 5 .9
OE, 94.6 ±3.8
in each .case replicates (n=20) of H^ labelled hormone were ex­
tracted from mixed plasma (0.2ml).
Dihydrotestosterone and T were also extracted quantitatively but 
as described in Methods section internal tritiated standards of each were 
added to individual samples to determine recoveries throughout the 
method which involved a chromatographic step. The recoveries of
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DHT and T are described under the chromatography section later in this 
chapter. Androstenedione, as shown in Table 3.1, was extracted with an 
efficiency of 80% ± 1.2%. All A assays were routinely corrected for a 
20% extraction loss.
2, Radioimmunoassay of C19 Androgens
a) ANDROSTENEDIONE
i) Separation of free and antibody bound steroid hormones.
In steroid radioimmunoassay one of the most critical steps is the 
separation of the free and antiserum bound steroid fractions following 
equilibration of antigen and antibody. Figure 3. 1 shows the standard 
curves obtained for A with different charcoal contact times (0, 10 
minutes and 20 minutes). Significant stripping occurred prior to 10 
minutes. Thereafter, a further significant reduction in the % bound did 
not occur. As a result 10 minutes contact time with DCC was employed 
in the A radioimmunoassay.
ii) Comparison of A radioimmunoassay with and without 
chromatography.
To confirm that the A antiserum was specific, aliquots from a 
pool of mixed plasma were assayed for A by the method as described in 
Methods Section, and compared with aliquots of the same plasma pool 
in which A was assayed using the same antiserum and conditions after 
purification of the plasma extract using column chromatography.
10 X 0.025ml aliquots of the plasma pool were extracted (after 
addition of an internal standard of tritium labelled A) with diethyl ether 
as described in Methods. These extracts were chromatographed indivi­
dually on columns (10 cm x 0.75 cm) of “ Lipidex R” (Packard-Becker 
Limited) with petroleum ether (boiling point 40° -  60°)/cyclohexane 
(95:5; v/v) as the eluting solvent. Under these conditions A is eluted
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between 12 and 15ml inclusive and is separated from all other C19 
androgens. The fractions 12ml -  18ml were eollected from the 
chromatogram of each aliquot, the solvent evaporated, an aliquot (25%) 
removed to determine chromatographic losses and the remainder was 
subjected to radioimmunoassay. Results were corrected for individual 
recoveries.
A further 10 x 0.025ml aliquots of the same plasma pool were 
extracted with hexane and subjected to direct radioimmunoassay as 
described in Methods. In this case each result was corrected for 80% 
recovery (Table 3.1). Table 3.II shows the mean and S.D. values 
obtained for the level of A in the mixed plasma pool when assayed by 
the two different methods.
Table 3.II
Androstenedione levels in Mixed Plasma Pool (pg/0.025ml)
Direct Assay With Chromatography
S.D.
64 65
58 56
59 68
53 58
48 75
51 54
50 67
56 85
58 52
61 12
55.8 63.7
5.16 10.44
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No significant difference was observed between the two sets of 
values and as a result the method without chromatography was used in 
this study.
iii) Statistical Assessment of the A Radioimmunoassay
The data obtained for the radioimmunoassay of A are listed
below.
1. Blank:- 1.4pg ±2.1pg (S.D.) n=72 / 0.05ml of ovariectomised, 
adrenalectomised plasma.
2. Sensitivity:- lOpg of cold A caused a significant drop in the %
bound and was distinguishable from the blank.
3. Intra-assay precision and accuracy:-
Twenty replicate standards of both 30pg and 70pg were added to
0.05ml of ovariectomised, adrenalectomised plasma and assayed 
within a single assay to give values of 32.3pg ±  5,3pg (S.D.) and 
72.5pg ±  6.5pg (S.D.) respectively.
These results gave values for accuracy and intra-assay precision 
of:- 30pg 70pg
Accuracy 107.7% ±  17.7% (S.D.) 103.6% ±  9.3% (S.D.)
Precision 16.4% 9.0%
4. Inter-assay precision
Four X 0.05ml aliquots from a mixed plasma pool were analysed 
with each assay and gave a cumulative value of 813pg/ml ±  71pg 
(S.D.)
Precision = 8.7%
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b) DIHYDROTESTOSTERONE AND c) TESTOSTERONE
i) Chromatography Column Recoveries
The recoveries of DHT and T achieved through the celite column 
partition chromatography were assessed by simultaneous chromato­
graphy of labelled standards of [4‘"^ C] DHT and [1-2H^] T. When the 
DHT and T fractions were collected (see Figure 2.3) and their radio­
active content determined the results shown in Table 3.Ill were 
obtained.
Table 3.III
Percentage recovery of [‘"^ C] DHT and [1-2H^] T after celite column 
partition chromatography.
[4'4Ç] DHT [1-2H^] T
Mean % recovery ±  SD (n=5)
DHT Fraction (6-25ml) 79 ±  5.3 0
T Fraction (36-50ml) 0 90 ±  7.3
ii) Method Recoveries
Internal standards of [1,2,4,5,6,TH^] DHT and [I-2H3] T were 
added to each
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sample prior to extraction. Immediately before radioimmunoassay 
aliquots were removed from both the DHT and T fractions for determin­
ation of radioactivity to compute recoveries up to that point -  i.e. to 
assess all methodological losses prior to radioimmunoassy. Table 3.IV 
shows the mean ±  S.D. % recoveries obtained.
Table 3.IV
Percentage recoveries of DHT and T prior to assay.
% Recovery
DHT 69.3 ±  7.5 (S.D.; n=90)
T 75.3 ±  5.0 (S.D.; n=90)
Each individual DHT and T fraction was corrected for its own recovery 
determined on an aliquot equal to that used for radioimmunoassay.
iii) Separation of free and antibody bound steroid hormones.
This separation was again achieved using DCC. Figures 3.2 and
3.3 depict the effect of different charcoal contact time (0, 10 minutes, 20 
minutes and 30 minutes) on the per cent bound radioactivity in the 
presence of 0, 50pg, lOOpg and 500pg of DHT (Figure 3.2) and 0, 20pg, 
lOOpg and 500pg of T(Figure 3.3).
In the case of T stripping occurred prior to 10 minutes whilst for 
DHT reduction of the per cent bound continued until 20 minutes. As a 
result of these findings the DCC contact times used in the assays were 10 
minutes for T and 20 minutes for DHT.
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iv) Statistical Assessment of DHT Assay
1. Blank:- 1.97pg ±  0.36pg (S.D.) n=30/0.05ml of ovariecto­
mised, adrenalectomised plasma.
2. Sensitivity:- The sensitivity limit for DHT was taken as that 
value which caused a significant displacement of the zero binding 
(Bo) and was distinguishable from the blank. For DHT this value 
was 8pg (90% of Bo).
3. Intra-assay precision and accuracy:-
Ten replicate standards containing 50pg and lOOpg of both T and 
DHT were added to 0.2ml of ovariectomised adrenalectomised 
plasma and assayed within a single assay. The values obtained for 
these plasmas and the resultant values for accuracy and precision 
at these two levels are shown in Table 3.V.
Table 3.V
pg of DHT
Amount added
Amount determined by assay
S.D.
n
Accuracy
Intra Assay Precision
50
51.0
± 6.1
10
102% ±  12.2% 
12.0%
100 
100.5 
±  11.6 
10
100.5% ± 11.6%
11.5%
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4. Inter-assay Precision:-
Eight X 0.2ml aliquots from a mixed plasma pool were analysed 
with each assay giving a cumulative value of 82.9pg ±  9.9pg (S.D,; 
n=104) and an inter-assay precision of 12.04%.
v) Statistical Assessment of T Assay
1. Blank:- 4.3pg ±  3.1pg (S.D.; n=30)/0.05ml of ovariectomised, 
adrenalectomised plasma.
2. Sensitivity:- lOpg cold T caused a significant drop in the 
binding of tritium labelled hormone (82% of B o s e e  Figure 3.2) 
and was distinguishable from the blank. This level was taken as 
the limit of sensitivity.
3. Intra-assay precision and accuracy
This was determined in the same assay as that for DHT above and 
the levels observed in spiked plasmas shown in Table 3.VI. gave 
the noted results for accuracy and precision.
Table 3.VI
pg of T
Amount added
Amount determined by assay
S.D.
n
Accuracy
Intra Assay Precision
50
56.3 
±  3.7 
10
112.6% ±  7.4% 
6 .6%
100
101.3 
±  8.4 
10
101.3% ±  8.4% 
8 .2%
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4. Inter-assay Precision;-
The cumulative value obtained for assay of a mixed plasma pool (8 
X 0.2ml/assay) was 2356pg ±  346pg (S.D.; n-104) which gives an 
inter-assay precision of ±  14.68%
3. Radioimmunoassay of P, 170H P and OE^.
These steroid hormones were assayed as described in Meth­
ods, using methods already in use in the Department of Obstetrics 
and Gynaecology. A summary of the precision, accuracy and sen­
sitivity data from these assays is shown in Table 3.VII.
Precision was determined in each assay at a point on the 
standard curve in the middle of the working range.
Table 3.VII
Statistical Assessment of Steroid Radioimmunoassays
P 170HP
Blank Value 17±2.3pg 12± 1.3pg 3.0±2.0pg
(S.D.; 11=52) (S.D.; n=51) (S.D.; n=50)
Lowest limits 20pg lOpg lOpg
of detection
Accuracy % 100+9.1 (n=51) 98.8 + 8.6 (n=50) 108.9± 11.12 (n=20)
Intra-assay + 9.2 (n=51) + 8 .7  (n=50) ±  10.2 (n=20)
precision
Inter-assay +  11.8 (n=53) ±  12.7 (n=53) + 11.3 (n=50)
precision
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3a) Radioimmunoassay of FSH, LH and PRL.
The protein hormones were kindly assayed by the Research 
Department, Glasgow Royal Maternity Hospital (FSH and LH -  
Dr. Philip England) and Clinpath Services Ltd., High Wycombe 
(PRL -  Dr. Alan Craig). Full details of the validation data for these 
assays are not included but all showed acceptable inter and intra 
assay precisions.
4. Androgen Profiles in the Normal Human Menstrual Cycle
Levels of A, DHT and T were determined in serial daily plasma 
samples obtained throughout seven cycles from volunteers. All of the 
samples from one cycle were determined in a single assay, for each 
hormone, to ensure that only intra-assay variation affected the results. 
0.05ml of each plasma sample was assayed for A, whilst DHT and T 
were assayed in 0.2ml of each plasma sample.
Figures 3.4, 3.5 and 3.6 show the mean levels ±  SEM in the 
seven normal menstrual cycles for A, DHT and T respectively.
These results are plotted relative to the day of the LH peak which 
was designated day 0. Days prior to this peak are signified as negative 
and days following it as positive.
The A levels (Figure 3.4) are fairly constant throughout the 
menstrual cycle showing levels between 1 and 2ng/ml. A rise in the 
level occurred at around mid cycle; the levels from day 0 to day 4 being 
elevated compared to those of previous and succeeding days. This early 
luteal peak was observed in all patients, but in this small series was not 
statistically significant. The highest mean value obtained was on day
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+2 and was 2.32 ±  0.4 (SEM) ng/mi. The levels in the late luteal phase 
and the early follicular phase were similar to each other.
Mean DHT levels (Figure 3.5) ranged from 100 to 173 pg/ml. 
The levels rose throughout the follicular phase from a base-line of 
lOOpg/ml to reach peak values of 173pg/ml on day -2 . Following a 
slight drop the levels rose again to reach an identical peak on day +2. 
Thereafter the levels declined slowly to basal values during the remaind­
er of the luteal phase.
The mean levels of T (Figure 3.6) ranged from 172 pg/ml to 579 
pg/ml. The pattern of T, particulary in the follicular phase, was similar 
to that described for DHT. T levels rose during the follicular phase 
from basal levels on day -8  to reach peak values at around mid cycle 
(day -1 , 527 ±  176 (SEM) pg/ml, day +1, 579 ± 97  (SEM) pg/ml). After 
day +1 levels declined until day +7 (296 ± 7 5  (SEM) pg/ml). The levels 
between days -2  and +4 being significantly higher than those between 
days -8  and -4  and days +5 and +7 respectively (p<0.01). Levels rose 
again in the late luteal phase to peak on day +14 (531 ±  85 (SEM) 
pg/ml). Following menstruation the levels declined until day -8  when 
the follicular rise described above began.
5. Levels of FSH, LH, 170H P, P and OE^ in daily Plasma Samples 
throughout the Normal Human Menstrual Cycle
The levels of FSH, LH, 170HP, P and OE^ were also determined
in the samples from the seven volunteers. The levels for all of these
hormones were not significantly different from their previously published
profiles (Coutts 1976) which were shown in Introduction (Figures 1.4,
1.5, 1.6, 1.7, 1.8).
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6. Prolactin Levels in the Normal Human Menstrual Cycle
Levels of human PRL were also determined throughout the 
normal cycles from the seven volunteers and the mean levels ±  SEM are 
shown in Figure 3.7. The levels ranged from approximately 280 to 450 
m lU /m l showing a small peak at mid cycle and a secondary rise in the 
late secretory phase. Despite these rises assessment of single samples
showed no significant differences throughout the cycle.
7. Dating of Stage of Menstrual Cycle in Patients Sampled at
Hysterectomy
The stage of the menstrual cycle was assessed, in patients undergo­
ing surgery, from the menstrual history, the macroscopic and microsco­
pic examination of the ovaries and the histological changes of the 
endometrium. Table 3. VIII lists the stage of the menstrual cycle assessed 
by each of these parameters in patients undergoing hysterectomy. This 
assessment of the stage of the menstrual cycle was confirmed from the 
levels in peripheral venous plasmas of LH, FSH, OE^ and P. Table 
3VIII also lists the conditions indicating surgery. In a few patients 
(Table 3.Villa) the information from the menstrual history, the ovaries 
and the endometrium was insufficient to achieve accurate assessment of 
the stage of the menstrual cycle. In these patients the assessment was 
based on what information was available regarding the above parameters 
and the levels of LH, FSH, P and OE^.
Using the information in Tables 3.VIII and 3.V illa the patients 
were designated as being in one of the six stages of the cycle -  early 
proliferative (EP), mid proliferative (MP), late proliferative (LP), early 
secretory (ES), mid secretory (MS) or late secretory (LS). Figure 3.8 is a 
schematic diagram of the normal menstrual cycle showing follicular and 
luteal phases and the division of these two phases into early, mid and 
late stages.
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8. Levels of Hormones in Peripheral and Ovarian Venous Samples 
obtained from Patients at Hysterectomy who had Normal Repro­
ductive Function.
As described above in Tables 3.VIII and 3.V illa, patients were 
grouped into EP, MP, LP, ES, MS and LS. The levels of the hormones 
in the peripheral and the ovarian venous samples are presented under 
these stages of the menstrual cycle for each hormone. Each hormone is 
described in two separate tables, one showing the levels in patients in the 
proliferative phase and the second those in patients in the secretory 
phase. The tables list the results in peripheral samples and in ovarian 
venous samples draining the active and/or the contralateral ovary. 
Where sufficient samples were, available mean ±  SEM values are listed 
for each stage of the cycle in the three different sites {P= peripheral vein; 
0=active ovarian vein; C - contralateral ovarian vein).
For the individual hormones the levels are described in the tables 
as follows:-
A. FSH Table 3.IX and 3.X
B. LH Table 3.XI and 3.XII
C. PRL Table 3.XIII and 3.XIV
D. P Table 3.XV and 3.XVI
E. 170HP Table 3.XVII and 3.XVIII
F. OE^ Table 3.XIX and 3.XX
G. A Table 3.XXI and 3.XXII
H. DHT Table 3.XXIII and 3.XXIV
I. T Table 3.XXV and 3.XXVI
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The results shown in Tables 3.IX to 3.XXVI are also depicted 
graphically, as histograms of the mean values ± SEM for each hormone 
at the six different stages of the menstrual cycle, in Figures 3.10 to 
3.18. Each Figure describes the results for one hormone in the same 
order as described for the tables. Figure 3.9 represents a key describing 
the symbols used in these histograms showing the designation used for 
peripheral vein (P), active ovarian vein (O) and contralateral ovarian 
vein (C), and also the abbreviations used to describe the six stages of the
menstrual cycle. Where single patient results showed wide variations 
from the results of other patients in the same group they have not been 
included in the histograms to prevent unnecessary skewing of the data. 
This explains the occurrence of a few minor discrepancies between the 
tabulated and diagrammatic data.
Figures 3.19 to 3.27 show the same data with the hormone levels 
in peripheral veins contrasted only with those in veins draining the 
active ovaries at different stages of the cycle.
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Table 3.IX
Levels o f FSH (m lU /m l) in Plasma Samples from
Patients in the Proliferative Phase
E.P/
M.P.
L.P/
PATIENT C.**
M.F. > 50 .0 >50.0
C.M. 6.6 7.4
C.A. 4.4 4.6
K.L, 9.2 8.0 10.3
Mean 17.68 17.67 10.3
SEM 10.99 10.99 -
J.S. 4.1 4.1
A.K. 6.0 8.4
A.McG. 10.3 10.1
S.K. >50.0 >50.0
S.M. 4.0 3.1
J.G. 5.3 4.6
Mean 13.37 6.55 27.5
SEM 7.49 1.63 -
M.M. >50.0 >50.0
V.B. 3.8
E.D. 6.7 6.3
A.M. 2.6 2.5
J.A. 4.7 4.1 5.8
C.S. 7.7 6.2
M.McG. 8.2 10.0
Mean 12.03 13.27 5.8
SEM 6.46 7.52 ~
* See Figure 3.9.
**P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
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E.S.
M.S.
L.S.=
Table 3.X
Levels o f FSH (m lU /m l) in Plasma Samples
from Patients in the Secretory Phase
PATIENT /).** 6).**
H.B. 5.8 10,2
E.P. >50.0 >50.0
A.B. 73.0 9.0 15.1
F.H. 3.8 4.7
I.D. 5.6 5.3
Mean 27.74 7.3 15.1
SEM 14.34 - -
E.M. 6.0 5.4
A.H. 4.8 4.5
M.H. 4.8 4.5
E.McA. 7.6 6.9
E.H. 6.3 6.5
M.R. 3.8 3.6
M.F. 4.8 5.3
M.M. 4.8 4.0 3.7
C.N. 7.8
A.B. 2.7 2.7 2.5
D.C. 11.6 15.6
Mean 5.91 5.86 4.2
SEM 0.73 1.3 1.2
M.T. 7.0 6.9
S.L. 3.9 2.0
Mgt.W. 4.1 4.3
J.H. >50.0 >50.0 >50.0
E.McJ. 3.5 29.0 2.8
M.W. 4.2 8.7
Mean"*"** 4.5 5.5 2.8
SEM 0.6 1.2 -
* See Figure 3.9
**P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein. 
*** Omitting JH results and in case of LS, O-EMcJ as well.
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E.P/
M.P.'
L.P.'
Table 3.XI
Levels of LH (mILf/ml) in Plasma Samples from
Patients in the Proliferative Phase
PATIENT P.** C.**
M.F. 11.6 6.5
C.M. 7.5 7.3
C.A. 5.5 7,2
K.L. 6.0 8.5 7.6
Mean 7.65 7.38 7.6
SEM 1.38 0.42 -
J.S. 3.1 6.0
A.K. 15.2 19.0
A.McG. 10.0 13.7
S.K. 52.0 34.3
S.M. 7.9 7.0
J.G. 4.5 4.9
Mean 15.45 11.15 20.15
SEM 7.52 3.22 -
M.M. 61.4 54.0
V.B. 2.0
E.D. 10.0 9.2
A.M. 2.0 2.0
J.A. 7.1 7.1 8.2
C.S. 51.8 47.5
M.McG. 40.5 34.0
Mean 24.97 25.63 8.2
SEM 9.60 9.17 —
* See Figure 3.9.
**P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
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Table 3.XÏI
E.S.$
M.S.
E.S.Ht
Levels of LH (mlU/ml) in Plasma Samples
from Patients in the Secretory Phase
PATIENT p  H t* 6L** C.**
H.B. 13.8 15.5
E.P. 41.5 41.0
A.B. < 2.0 4.6 2.6
F.H. 4.1 4.7
I.D. 9.4 12.5
Mean 14,16 9.33 21.8
SEM 7.39 2.77 -
E.M, 11.7 9.4
A.H. 2.8 4.6
M.H. 6.4 3.5
E.McA. 21.7 21.0
E.H. 2.1 2.0
M.R. 7.1 10.5
M.F. 10.4 10,6
M.M. 5.9 7,5 8.9
C.N. 5.1
A.B. 3.4 3.0 4.3
D.C. 38.3 43.5 49.5
Mean 10.45 12.62 16.2
SEM 3.25 4.26 10.43
M.T. 28.3 5.5
S.L. 10.7 2.0
Mgt.W. 7.0 7.2
J.H. 8.6 10.4 9.8
E.McJ. 5.5 3.5 2.1
M.W. 3.6 4.2
Mean 10.6 5.5 6.0
SEM 3.67 1.2 -
* See Figure 3.9.
**P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein,
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Table 3.XII1
Levels of PRL (mlU/ml) in Plasma Samples
from Patients in the Proliferative Phase
E.P.* PATIENT P.** O** C**
M.F. 4290 4600
C.M. 4100 3800
C.A. 5600
IC.L. 3000
M.P.'
L.P.'
Mean
SEM
4248
534
4200
J.S. 3860 370
A.K. 4000 6200
A.McG. 1100
S.K. >8000 3500
S.M. 2400 3400
J.G. 1580 1640
Mean 3490 3750 1935
SEM 1021 1328 -
M.M. 2480
V.B. 2400
E.D. 3800 3000
A.M. 2600 5000
J.A. 7920 3100
C.S. 8000
M.McG. 2700 2200
Mean 4271 3325 -
SEM 969 594
See Figure 3.9.
'*"*‘P=peripheral plasma; <9=active ovarian vein; C=contralateral ovarian vein.
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Table 3.XIV
Levels of PRL (mlU/ml) in Plasma Samples
E.S.'
M.S.'
L.S.'
from Patients in the Secretory Phase
PATIENT 6).** (:.**
H.B, 4140 5600
E.P. 4400
A.B. 4520 6900 4600
F.H. 3060 3800
I.D. 2500 3000
Mean 3324 4824 4600
SEM 752 880
E.M. 1000
A.H. 7420 7000
M.H. 2620 3100
E.McA. 5440 3400
E.H. 1720 3200
M.R. 4100
M.F. 2300
M.M. 6400
C.N. 1920 2040
A.B. 1800 2300
D.C. 1500 1720 3200
Mean 3300 3504 3080
SEM 660 922 180
M.T. 2300 2880
S.L. 8000 7000
Mgt.W. 4400 4300
J.H. 3400 4600
E.McI. 2400 1660 1660
M.W. 1200 1220
Mean 3600 3610 1660
SEM 982 874
* See Figure 3.9.
'*'*P=peripheral plasma; (9=active ovarian vein; C=contralateral ovarian vein.
Table 3.XV
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E.P.'
L.P.
Levels of P (ng/ml) in Plasma Samples from
Patients in the Proliferative Phase
M.P.'^
PATIENT /).**
M.F. 0.6 1.8
C.M. 0.3 2.2
C.A. 1.0 0.6
K.L. 0.7 0.3 0.3
Mean 0.65 1.2 0.3
SEM 0.14 0.46 -
J.S. 0,85 1.3
A.K. 0.75 10.0
A.McG. 2.0 5.0
S.K. 2.5 1.6
S.M. 2.8 5.8
J.G. 0.4 1.5
Mean 1.56 5.58 1.45
SEM 0.41 1.75
M.M. 0.52 1.3
V.B. 0.22 2.4
E.D. 3.5 5.0
A.M. 0.8
J.A; 5.0 8.5 0.5
C.S. 0.6 4.3
M.McG. 1,4 1.25
Mean 1.87 3.36 0.5
SEM 0.79 1.05
*  See Figure 3.9.
'*'*P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
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E.S/
M.S.
L.S.'^
Table 3.XVI
Levels of P (ng/ml) in Plasma Samples from
Patients in the Secretory Phase
PATIENT P.** <C**
H.B. 3.5 14.0
E.P. 3.5 1.3
A.B. 3.5 14.0 3.75
F.H. 1.1 6.6
I.D. 5.3 21.0
Mean 3.38 13.9 2.5
SEM 0.67 2.9 —
E.M. 2.9 13.2
A.H. 6.0 300.0
M.H. 11.5 19.0
E.McA. 1.5 13.0
E.H. 1.1 0.6
M.R. 11.0 24.0
M.F. 2.1 140.0
M.M. 14.5 140,0 11.0
C.N. 1.7 15.0
A.B. 2.2 80.0 2.3
D.C. 2.8 140.0
Mean 5.2 88.4 4.6
SEM 1.45 29.5 3.2
M.T. 6.0 8.5
S.L. 1.8 12.0
Mgt.W. 2.6 60.0
J.H. 8.0 2.8
E.McI. 2.3 26.0
M.W. 2.25 9.6
Mean 2.99 20.7 2.8
SEM 0.76 8.33 -
* See Figure 3.9.
**P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
Table 3.XVII
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E.P.
M.P.=
L.P.'
Levels of 170HP (ng/ml) in Plasma Samples from
Patients in the Proliferative Phase
PATIENT 6L** C.**
M.F. 1.60 1.92
C.M. 1.90 2.92
C.A. 2.72 3.44
K.L. 3.30 4.40 3.64
Mean 2.38 3.18 3.64
SEM 0.39 0.52 -
J.S. 3.4 3.36
A.K. 1.68
A.McG. 0.86 9.3
S.K. 20.6 4.0
S.M. 1.54 4.9
J.G. 2.2 18.0
Mean 5.05 10.7 3.68
SEM 3.13 3.84 —
M.M. 1.3 4.06
V.B. 4.56 5.50
E.D. 2.88 6.60
A.M. 2.02
J.A. 5.40 12.60 5.50
C.S. 4.8 7.20
M.McG. 3.92
Mean 3.56 7.2 5.5
SEM 0.58 1.5 -
* See Figure 3.9.
*'*'P=peripheral plasma; 0-active ovarian vein; C=contralateral ovarian vein.
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E.S/
M.S.
L.S.'
Table 3.XVIII
Levels of 170HP (ng/ml) in Plasma Samples from
Patients in the Secretory Phase
PATIENT P.** 0 * * C.**
H.B. 2.32 4.5
E.P. 3.32 2.52
A.B. 0.86 2.28 1.20
F.H. 1.58 5.6
I.D. 3.52 3.88
Mean 2.32 4.07 1.86
SEM 0.5 0.69 -
E.M. 2.6 7.4
A.H. 3.04 > 100.0
M.H. 2.92 18.2
E.McA. 1.60 5.0
E.H. 5.6 4.2
M.R. 2.02 5.4
M.F. 2.14 40.0
M.M. 3.48 40.0 3.92
C.N 1.48 12.0
A.B. 3.36 >100.0 3.84
D.C. 1.82 > 100.0
Mean 2.73 42.8 3.99
SEM 0.35 13.1 0.11
M.T. 4.12
S.L. 2.08 3.76
Mgt.W. 2.44 11.40
J.H. 2.16 3.44 3.48
E.McI. 2.20 3.24 2.28
M.W. 3.44 4.3
Mean 2.74 5.23 2.88
SEM 0.34 1.55 -
See Figure 3.9.
**P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
Table 3.XIX
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Levels of OE., (pg/ml) in Plasma Samples from
E.P.
M.P.'
L.P.'
Patients in the Proliferative Phase
PATIENT P** 6)** (%**
M.F. 58 410
C.M. 58 1550
C.A. 50 700
K.L. 118 480 450
Mean 71.0 785.0 450.0
SEM 15.78 262.0 —
J.S. 125 490
A.K. 80 1030
A.McG. 60 3880
S.K. 73 500
S.M. 105 1200
J.G. 110 3030
Mean 92.2 2285.0 495.0
SEM 10.2 698.0 -
M.M. 66 300
V.B. 112 400
E.D. 140 500
A.M. 50 300
J.A. 110 420 200
C.S. 160 990
M.McG. 120 650
Mean 108.3 508.6 200.0
SEM 14.7 92.4 -
*  See Figure 3.9.
**P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
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E.S.'
M.S.'
L.S.'
Table 3.XX
Levels of OE., (pg/ml) in Plasma Samples from
Patients in the Secretory Phase
PATIENT p  ** 0.** c:.**
H.B. 115 1280
E.P. 45 430
A.B. 70 780 1100
F.H. 75 500
I.D. 70 600
Mean 75.0 790.0 765.0
SEM 11.6 173.0
E.M. 86 1680
A.H. 86 2550
M.H. 93 900
E.McA. 58 850
E.H. 250 1350
M.R. 183 780
M.F. 170 25000
M.M. 120 1180 430
C.N. 69 1250
A.B. 106 4350 480
D.C. 183 5000
Mean 128.0 2060.0*'^* 753.0
SEM 18.0 529.0 299.0
M.T. 120 690
S.L. 35 585
Mgt.W. 68 980
J.H. 600 500
E.McI. 115 1580 350
M.W. 70 430
Mean 81.6 810.8 425.0
SEM 15.9 170.8
* See Figure 3.9.
' '^^P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
Value from MF is not included in this calculation
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E.P/
M.P.
L.P.*
Table 3.XXI
Levels of A (ng/ml) in Plasma Samples from
Patients in the Proliferative Phase
PATIENT P.** O.** C.**
M.F. 1.95 2.5
C.M. 1.85 7.5
C.A. 2.47 4.2
K.L. 2.86 3.75 2.98
Mean 2.28 4.49 2.98
SEM 0.23 1.07 -
J.S. 2.05 3.50
A.K. 2.2 8.26
A.McG. 1.5 7.76
S.K. 2.5 3.5
S.M. 1.06 3.80
J.G. 3.83 13.26
Mean 2.19 8.3 3.5
SEM 0.39 1.9 —
M.M. 1.4 7.66
V.B. 2.25 12.01
E.D. 2.5 4.72
A.M. 1.38 6.66
J.A. 2.35 7.25 2.25
C.S. 4.0 9.5
M.McG. 3.2 7.0
Mean 2.44 7.8 2.25
SEM 0.35 0.88 -
* See Figure 3.9.
**P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
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Table 3.XXH
Levels of A (ng/ml) in Plasma Samples from
Patients in the Secretory Phase
E.S/
M.S.'
L.S.
PATIENT JO.** O,** c.**
H.B. 3.1 6.9
E.P. 2.9 3.0
A.B. 1.01 6.8 1.18
F.H. 2.95 10.88
I.D. 3.03 7.26
Mean 2.6 7.96 2.09
SEM 0.40 0.98 -
E.M. 2.45 20.1
A.H. 2.28 49.1
M.H. 2.95 31.2
E.McA. 2.78 30.5
E.H. 1.70 3.43
M.R. 2.6 12.0
M.F. 1.93 195.1
M.M. 1.51 18.0 3.8
C.N. 3.10 32.0
A.B. 2.61 50.0 2.86
D.C. 2.51 29.3 13.24
Mean 2.40 46.7 5.83
SEM 0.15 16.9 2.00
M.T. 1.61 3.1
S.L. 2.25 3.28
Mgt.W. 4.5 8.0
J.H. 1.56 7.3 2.0
E.Mcl. 3.45 10.71
M.W. 2.93 5.5
Mean 2.72 6.3 2.0
SEM 0.5 1.2 -
See Figure 3.9.
**P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
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E.P/
M.P.'
L.P.'
Table 3.XXIII
Levels of DHT (pg/ml) in Plasma Samples from
Patients in the Proliferative Phase
PATIENT P.** <C.**
M.F. 141 193
C.M. 141 276
C.A. 140 187
K.L. 113 377 268
Mean 133.8 258.0 268.0
SEM 6.9 44.0 -
J.S. 122 366
A.K. 145 355
A.McG. 119 367
S.K. 90 173
S.M. 93 198
J.G. 231 1350
Mean 133.0 568.0 270.0
SEM 21,0 264.0 —
M.M. 93 235
V.B. 106 581
E.D. 168 192
A.M. 146 220
J.A, 219 394 239
C.S. 194 302
M.McG. 108 424
Mean 148.0 335.0 239,0
SEM 18.0 53.0 -
* See Figure 3.9.
**P=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
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E.S/
M.S.'
L.S.*
Table 3.XX1V
Levels of DHT (pg/ml) in Plasma Samples from
Patients in the Secretory Phase
PATIENT p  HsHs (:.**
H.B. 141 499
E.P. 86 133
A.B. 103 471 127
F.H. 162 578
I.D. 93 439
Mean 117.0 497.0 130.0
SEM 14.7 30.0 -
E.M. 179 944
A.H. 182 1433
M.H. 131 796
E.McA. 138 730
E.H. 159 199
M.R. 164 473
M.F. 121 2549
M.M. 160 677 245
C.N. 182 514
A.B. 132 741 335
D.C. 134 1306
Mean 153.0 1016.3 260.0
SEM 7.0 196.5 97.5
A.T. 140 392
S.L. 118 225
Mgt.W. 125 484
J.H. 146 250 261
E.McI. 220 614
M.W. 196 269
Mean 158.0 372.0 261.0
SEM 67.0 63.0 -
* See Figure 3.9.
**p=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
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E.P/
M.P.*
L.P.'
Table 3.XXV
Levels of T (pg/ml) in Plasma Samples from
PATIENT
M.F,
C.M.
C.A.
K.L.
Patients in the Proliferative Phase
314 255 
316 562 
171 357 
184 400
C **
Mean 246.0 394.0
SEM 40.0 64.0 -
J.S. 279 276
A.K. 363 479
A.McG. 151 585
S.K. 389 1220
S.M. 233 285
J.G. 577 935
Mean 332.0 571.0 748.0
SEM 60.4 136.0 -
M.M. 586 3723
V.B. 636 451
E.D. 324 472
A.M. 574 419
J.A. 428 1938 414
C.S. 595 723
M.McG. 416 1797
Mean 508.0 1360.0 414.0
SEM 44.0 463.0 -
* See Figure 3.9.
**p=peripheral plasma; 0=active ovarian vein; C=contralateral ovarian vein.
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M.S.
L.S.
Table 3.XXVI
Levels of T (pg/ml) in Plasma Samples from
Patients in the Secretory Phase
E.S.* PATIENT
H.B.
E.P. 
A.B.
F.H.
I.D,
E.M.
A.H.
M.H.
E.McA.
F.H. 
M.R. 
M.F. 
M.M.
C.N.
A.B.
D.C.
M.T.
S.L.
Mgt.W.
J.H.
E.McI.
M.W.
Mean
SEM
Mean
SEM
Mean
SEM
p  *Ht 0.**
631 367
334 300
182 243 200
482 1285
184 1562
363.0 864.0 250.0
87.0 329.0 -
171 1467
393 2215
464 2809
404 1146
489 1257
624 983
369 3225
239 590 664
232 1100
205 1657 596
205 5160
345.0 2041.0 839.0
44.0 435.0 210.0
314 428
331 388
319 576
381 273 488
294 434 422
236 446
313.0 422.0 455.0
19.0 40.0 -
* See Figure 3.9.
**P=peripheral plasma; D=active ovarian vein; C=contralateral ovarian vein.
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From these results (Tables 3.IX to 3.XXVI and Figures 3.10 to 
3.27) a number of points may be drawn with respect to the relative 
levels of each hormone in peripheral venous plasma, plasma from veins 
draining the active ovary and plasma from contralateral ovarian veins. 
These points are made below for each hormone using the same alphabe­
tical key A to I as used previously.
A. FSH
B. LH
C. PRL
D. P
E. 170HP
F. OE^
G. A
H. DHT
I. T
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A. FSH
The levels of FSH found in the peripheral plasmas of the patients 
in the six stages of the menstrual cycle (Figures 3.10 and 3.19) are 
consistent with those found in peripheral plasma from normally 
menstruating volunteers (Figure 1.4) showing highest levels in the early 
proliferative phase followed by a reduction as the cycle progresses. At 
all six stages no significant differences were observed between the levels 
in plasmas draining active ovaries and those in peripheral plasmas.
Where contralateral ovarian venous plasmas were available, their levels 
were again not significantly different from the peripheral values.
B. LH
In samples from normally menstruating volunteers LH levels peak 
around mid cycle (Figure 1.5). Maximum levels of LH were observed in 
these patients in the late proliferative stage of the cycle (Figures 3.11 and 
3.20). No significant difference' was observed in any case between the 
LH values in plasmas draining active ovaries and those in peripheral 
plasmas. In the small number of contralateral ovarian venous plasma 
samples studied levels were also not significantly different from these in 
peripheral plasma.
C. PROLACTIN
Levels of PRL observed in the samples obtained from these 
patients at surgery were considerably elevated compared to normal cycle 
plasma levels obtained from volunteers (Figure 3.7); the levels at surgery 
being some four to five times higher. This was presumably a response to 
anaesthetics and will be discussed in the Discussion. Despite these 
elevation it can be seen (Figures 3.12 and 3.21) that the levels were 
constant throughout the cycle and no significant difference was observed
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between the levels in plasma from the active ovarian vein, the peripheral 
vein or the contralateral ovarian vein.
D. PROGESTERONE
As found in sampes from normally menstruating volunteers (Fi­
gure 1.8), plasma obtained during the secretory phase of the cycle 
contained much higher levels of P than that obtained in the proliferative 
phase. The levels in the peripheral plasmas were consistent with normal 
menstrual cycle data showing peak levels of greater than 5ng/ml in the 
MS phase (Figures 3.13 and 3.22). There was also evidence of increased 
P levels in the MP and LP phases prior to ovulation. In the plasma 
samples obtained from veins draining active ovaries a similar picture was 
obtained but levels of P of up to seventeen times the peripheral levels 
were found during the secretory phase. In the MP and LP phases the 
levels of P were also greater in active ovarian venous plasmas than in 
the peripheral venous samples.
Levels in contralateral ovarian venous plasmas, where sampled, 
were not at any stage of the cycle significantly different from the levels in 
the peripheral plasma (Figure 3.13). The levels of P in plasma from 
veins draining active ovaries were significantly higher than those in 
plasmas from peripheral or contralateral ovarian veins in the MP phase 
(p<0.05) and in the MS phase (p<0.02).
E. 17a HYDROXYPROGESTERONE
Levels of 170HP in peripheral venous samples obtained from 
patients at surgery showed a rise in the LP phase (mean 3.56ng/ml) 
followed by a fall in the ES phase and a secondary rise in the MS and LS 
phases (ca 2.7ng/ml) (Figures 3.14 and 3.23). This pattern is in agree­
ment with the findings in normally menstruating volunteers for 170HP
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(Figure 1.7). At all stages of the cycle studied, apart from the EP, the 
levels of 170H P in plasmas from veins draining active ovaries were 
higher than those in peripheral plasmas -  maximum levels were found in 
the MS stage, where the mean level in the active ovarian vein was 42.8 
ng/ml, a value sixteen times that obtained in corresponding peripheral 
plasma samples.
The levels from the active ovary were significantly higher than 
those in peripheral plasmas in MP and LP (p<0.05) and MS (p<0.01) 
phases. Contralateral ovarian venous levels, where examined, were 
higher than the corresponding peripheral plasma levels in the MP and 
MS stages of the cycle. These increases in the contralateral ovarian 
veins were not significant (p<0.1).
F. OESTRADIOL
As observed in samples obtained from normally menstruating 
volunteers, OE^ levels rose during the proliferative phase to peak at mid 
cycle. Following a nadir, peak levels were again observed in the MS 
phase (Figures 3.15 and 3.24). The mean levels assayed in the peripher­
al samples from the patients studied at surgery in the LP (108pg/ml) and 
MS phases (128pg/ml) were considerably lower than equivalent levels 
measured in normally cycling volunteers (Figure 1.6).
The OE^ levels in venous plasmas draining active ovaries were 
higher than those in peripheral plasmas at all six stages of the menstrual 
cycle; the pattern of levels being similar to that observed in the normal 
menstrual cycle with the exception that the proliferative phase peak was 
found in the mid rather than the late stage (Figure 3.15). Oestradiol 
levels in the veins draining the active ovaries were significantly higher at 
all stages of the cycle except EP than corresponding peripheral plasma 
levels (MP, ES and LS ~ p<0.01 ; LP, MS -  p < 0.005).
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Levels of OE^ in contralateral ovarian veins were also higher than 
the corresponding peripheral venous levels. Where sufficient contrala­
teral ovarian venous samples were available to allow statistical assess­
ment, the levels in the contralateral ovarian veins were significantly 
higher than those in peripheral plasmas (p<0.05). The mean OE^ 
levels from veins draining active ovaries were up to twenty five times 
higher than the corresponding peripheral levels (MP) whilst the contrala­
teral ovarian venous levels were greater than the peripheral levels by up 
to nine times (ES).
G. ANDROSTENEDIONE
Androstenedione levels in the samples from normally menstruat­
ing volunteers (Figure 3.4) were fairly constant throughout the cycle with 
a minor rise in the ES phase. The A levels observed in samples of 
peripheral plasma obtained from patients at surgery were consistent with 
those findings; similar levels being observed at all six stages of the cycle, 
with the secretory phase levels slightly higher than those in the prolifera­
tive phase (Figures 3.16 and 3.25).
At all six stages of the cycle levels of A in venous plasmas drain­
ing active ovaries were higher than the corresponding peripheral levels; 
this difference was highly significant at all stages except in thé EP (MP 
-p < 0 .0 2 ; LP and MS -  p <  0.001; ES -  p<  0.005; LS -  p<0.05). Levels 
of A in active ovarian venous plasmas were highest during the secretory 
phase, the levels in the MS phase being more than twelve times the 
corresponding peripheral venous levels. Active ovarian venous levels of 
A were also elevated during the proliferative phase being 3-4 times the 
corresponding peripheral levels in the MP and LP phases.
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Contralateral ovarian vein levels of A, where available, were iden­
tical to peripheral levels except in the MS stage where a small, but signi­
ficant, elevation was observed (p<0.02). Although A levels in. contra­
lateral ovarian veins were increased at this stage of the cycle they were 
insignificant compared to the levels at the same stage in active ovarian 
venous plasmas (p<0.01).
H. DIHYDROTESTOSTERONE
Levels of DHT in peripheral venous plasma samples, obtained 
from patients at surgery, were constant throughout the EP and MP 
phases, rose slightly in the LP stage, decreased during the ES phase and 
rose again in the MS and LS stages (Figures 3.17 and 3.26). This 
pattern was consistent with that described earlier for peripheral samples 
from normally menstruating volunteers (Figure 3.5) and levels assayed 
(lOOpg/ml -  200pg/ml) were similar.
Dihydrotestosterone levels in plasmas from veins draining active 
ovaries were higher than corresponding peripheral plasma levels at all 
six stages of the cycle. This increase, as in the case of A, was significant 
at all stages of the cycle except the EP(MP and LS -  p<0.02; LP -  
p<0.01; ES and MS - p <  0.001). The highest DHT levels in active 
ovarian veins were observed in the MS phase where they were more 
than six times the corresponding peripheral levels. Levels of DHT in 
contralateral ovarian venous plasmas, where sampled, were identical to 
or slightly higher than those in corresponding peripheral plasmas. The 
level in contralateral ovarian veins compared to corresponding peri­
pheral veins was significantly higher in the MS phase (p<  0.005).
118
L TESTOSTERONE
The mean levels of T in the peripheral venous samples from 
patients at surgery rose from the beginning of the cycle to peak in. the LP 
phase. Levels during the secretory phase were lower than those at mid 
cycle but were still elevated compared to those in the EP stage (Figures 
3.18 and 3.27). This pattern of T in peripheral venous samples was 
similar to that described previously (Figure 3.6) for peripheral venous 
plasma from normally menstruating volunteers.
The levels of T in plasmas from veins draining active ovaries were 
higher than those in corresponding peripheral venous plasmas at all six 
stages of the cycle (Figure 3.27) being significantly so in the MP 
(p<0.02) the MS (p < 0.005) and the LS (p<0.05) stages. The values for 
p at the other stages of the cycle where the increase in T was not statisti­
cally significant were all less than 0.2.
Testosterone levels in plasmas from veins draining contralateral 
ovaries, where sampled, were similar to their corresponding peripheral 
plasma levels except in the MS and LS phases where they were signifi­
cantly higher than the peripheral values (MS -  p<0.01; LS 
-p< 0 .02). In the LS and MP stages the contralateral ovarian venous 
plasma levels of T were higher than those in plasmas from veins drain­
ing the active ovaries but the differences were not statistically significant.
8. a) Hormone Levels in plasmas from veins draining both ovaries and
in peripheral plasma from the same patient.
Tables 3.IX to 3.XXVI show levels of the various hormones in 
peripheral plasmas and in plasmas from veins draining active and 
contralateral ovaries. However, in many of the patients only one
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ovarian vein was sampled. The use of such data to draw conclusions 
with regard to the relative hormone concentrations in the two ovarian 
venous effluents might be subject to criticism. In a number of patients 
samples from veins draining both ovaries were obtained. Table 3.XXVII 
shows the levels of the six steroid hormones assayed in peripheral venous 
plasmas and plasmas from ovarian veins in six patients in whom bilater­
al ovarian samples were obtained. These patients represent the entire 
menstrual cycle with patients in all stages except MP. The Table also 
shows Means ±  SEM for each hormone P ,0  and C samples from all of 
these patients. The levels of P and 170HP were not significantly differ­
ent between peripheral and contralateral venous plasmas. In the active 
ovarian venous effluents the levels of P and 170HP were higher than 
those from the other two plasmas in all patients except the one in the EP 
stage. The levels of P and 170HP in active ovarian venous plasmas 
were significantly higher in the other five patients (p<0.05 for both 
hormones). As was expected for progestogens the increases were most 
marked during the secretory phase. Oestradiol levels in venous plasmas 
draining active ovaries were significantly higher than those in both 
peripheral and contralateral venous plasmas at all stages (p< 0.005). In 
addition, however, although significantly lower than active ovarian 
venous levels, the concentrations in contralateral ovarian venous plasmas 
were significantly higher than the peripheral venous levels at all stages of 
the cycle (p<0.02).
Androstenedione levels in peripheral plasma were not significantly 
different from those in contralateral ovarian venous plasmas at any stage 
of the cycle. The active ovarian vein levels of A were higher than both 
the peripheral and contralateral vein levels at all stages. The active 
ovarian vein increase in A concentrations was most marked at the MS 
stage and was significant throughout the cycle (p<0.02).
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Active ovarian venous plasma levels of DHT were significantly 
higher than those in either contralateral or peripheral venous samples at 
all stages of the cycle (peripheral p<0,05; contralateral p<0.02). The 
levels in contralateral ovarian veins were higher than those in peripheral 
plasmas at all stages but in the small series studied this difference was 
not significant (p<0.1).
Testosterone levels were variable throughout the cycle. The only 
increase associated with the active ovarian venous effluent was in the 
patient in the LP stage when maximal levels of T were observed in 
normally menstruating volunteers (Fig. 3.6). The levels of T in contrala­
teral ovarian veins were higher than those in peripheral veins in most of 
the samples, particularly late in the cycle when contralateral ovarian 
venous levels were at least as high as those in active ovarian venous 
effluents. None of these T differences were significant in the series 
described in Table 3.XXVII.
9) Hormone Levels in the Ovarian Artery
To determine whether the levels of the steroid hormones 
examined in this study increased during passage through the ovary 
plasmas were obtained from the peripheral vein and also the ovarian 
artery and ovarian vein, supplying and draining the active ovary, in one 
patient. The levels of hormones in the peripheral and ovarian veins 
and the ovarian artery in this patient who was in the LP stage of the 
cycle are shown in Table 3.XXVIII. The levels of all of the hormones 
were identical in the peripheral vein and the ovarian artery whereas in 
the ovarian vein, the levels of OE^, A and P were considerably elevated 
whilst those of DHT and 170HP were slightly elevated.
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Table 3.XXVIII
Hormone levels in peripheral and ovarian veins 
and in ipsi lateral ovarian artery
Hormone Peripheral Ovarian Ovarian
Vein Artery Vein
P (ng/ml) 0.22 0.25 2.4
OE^ (pg/ml) 113 130 400
170HP (ng/ml) 4.56 4.38 5.50
A (ng/ml) 2.25 2.31 12.01
DHT (pg/ml) 106 144 381
T (pg/ml) 436 424 451
10. Hormone Levels in Peripheral Plasma Samples 
Before and After Ovariectomy
In one patient, in the EP phase, the contribution of the ovaries to 
the levels of steroid hormones in peripheral plasma v^as assessed by 
assaying the hormone levels in peripheral plasma obtained at surgery, 
prehysterectomy and for six days after bilateral ovariectomy. The levels 
of the six steroid hormones in these plasma samples are shown in Table 
3.XXIX.
Hormone
Table 3.XXIX
Levels of steroid hormones in peripheral plasmas 
pre and post ovariectomy 
in a patient in the early proliferative stage
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170HP OE, DHT
(ng/ml) (ng/ml) (pg/ml) (ng/ml) (pg/ml) (pg/ml)
Sample
Before removal 
of ovaries
0.70 3.30 110 2.98 200 526
Post Ovariectomy
Day 1 0.30 0.62 58 0.98 119 190
Day 2 0.20 0.56 68 0.78 141 207
Day 3 0.25 0.48 60 0.80 132 257
Day 4 0.35 0.64 55 1.23 149 259
Day 5 0.25 0.48 56 1.10 151 215
Day 6 0.35 0.50 64 1.13 123 255
These results show that the levels, of all six steroid hormones 
measured, were reduced in the post ovariectomy samples even although 
this patient was in the least active stage of the cycle. The levels of P, 
OE^, DHT and T, were about 50% of their pre-ovariectomy values, 
those of 170HP were 20% of the pre-ovariectomy level and A values 
were 33% of their pre-ovariectomy level following surgical removal of 
the ovaries.
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11. Hormone Levels in Fluid from a Corpus Luteum
In a patient at hysterectomy, who was categorised as being in the 
late secretory phase, difficulties were experienced in obtaining ovarian 
venous samples from either ovary. However, the corpus luteum was 
clearly visible in the right ovary and the luteal fluid from this was aspir­
ated at the same time as a sample of peripheral venous blood was collec­
ted. Figure 3.28 shows histograms comparing the levels of the nine 
hormones in the luteal fluid with those in the peripheral venous 
plasma. The luteal fluid contained small amounts of the three protein 
hormones but at considerably lower concentrations than were present in 
the peripheral plasma. However, in the case of all six steroid hormones 
much higher concentrations were observed in the luteal fluid than in the 
peripheral plasma; luteal fluid levels being of the order of 4.5 times 
higher for all steroid hormones even although this corpus luteum was 
presumably regressing.
12. Levels of Hormones in Peripheral Plasmas and Ovarian Fluids
obtained at Hysterectomy from Patients who had Apparently
Abnormal Cycles
i) POLYCYSTIC OVARIAN DISEASE
Two patients were sampled in whom both of the ovaries on 
macroscopic and microscopic examination were found to contain multi­
ple ovarian cysts. Unlike many patients with polycystic ovarian disease 
(McConway et al 1977) they both had ovulatory cycles and were categor­
ised as being in the secretory phase -  DC (MS), EMcN (LS). The 
presence of a corpus luteum in both of these patients allowed the active 
ovary to be identified although both ovaries were cystic. Figures 3.29 
and 3.30 show the levels of the nine hormones in plasma samples from 
peripheral and both ovarian veins in these two patients. As shown
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previously, for patients in the MS and LS stages of the normal cycle, 
levels of all six of the steroid hormones assayed were significantly elevat­
ed in the plasmas from the veins draining the active ovaries compared to 
the peripheral plasma levels. However, in these two patients with 
polycystic ovarian disease, in contrast to the normal patients, elevated 
levels of all steroid hormones were also found in the plasmas from the 
veins draining the contralateral ovaries. The levels in the contralateral 
ovarian veins were less than those in the active ovarian veins but were 
higher than those in the peripheral plasma; much higher in the patient 
in the MS phase than in the one in the LS phase.
ii) PATIENT W ITH PRIMARY INFERTILITY AND HIRSUTISM 
Patient E.W. aged 30, with a history of primary infertility and 
clinically hirsute, had a laparotomy performed for an ovarian mass, 
detected on examination under anaesthesia. At operation an ovarian 
tumour was found on the right ovary. The origin of the tum our which 
was fluid-filled was indeterminate but Pathology stated that it was “not 
a granulosa cell tum our” . A sample of the tumour fluid, plasma from 
the ovarian venous effluent draining the same ovary and a peripheral 
venous plasma sample were collected.
Hormone levels found in these samples are shown in Figure 
3.31. On the basis of the patient’s menstrual history, the macroscopic 
and microscopic appearance of the ovaries and the histology of the 
endometrium this patient was classified as being in the LP of the cycle. 
The levels of P, 170HP, LH and FSH in the peripheral and ovarian 
venous samples were consistent with the LP phase of the cycle. Oestra­
diol and A levels were considerably higher, in both peripheral and
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ovarian venous samples, than the levels observed in normal patients at 
the same stage of the cycle (Figures 3.15 and 3.16).
High levels of steroid hormones were present in the tumour fluid -  
especially OE^ and the three androgens. These levels were much higher 
than those observed in the ovarian venous plasma.
13. Hormone Levels in Samples obtained at Hysterectomy from
Patients who were not Cycling Normally.
i. PATIENTS WHO HAD BEEN TAKING ORAL
CONTRACEPTIVES.
Three patients who were taking oral contraceptives (variable; of 
the mixed oestrogen/progestogen type) until four days pre-operation 
were studied. These patients were (1) A C. who was operated upon on 
day five of the cycle and had been on the ‘Pill’ for seven years. Being on 
day five she was at the stage of the cycle when she would not normally 
have been taking the ‘Pill’. (2) A.W. who was operated upon on day 
fourteen of the cycle and had stopped taking the ‘Pill’ four days prior to 
operation. She had been on the ‘Pill’ for six months. (3) C.E. who was 
operated upon on day twenty four of the cycle and had been on the ‘Pill’ 
for an indeterminate period until stopping four days prior to operation. 
From each of the latter two patients a retention cyst greater than 2cm in 
diameter was found in one of the ovaries. [It was of interest that in 
another patient, who was included in the normal cycle late secretory 
group (J.H.), who had been on the ‘Pill’ for more than ten years until 
stopping four months before the operation a similar sized retention cyst 
was found.]
Samples were obtained at hysterectomy in these patients from 
peripheral and at least one ovarian veins. Where a retention cyst was
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found, the cyst fluid therein was also collected. (Cyst fluid was also 
obtained from J.H.).
The hormone levels found in patient A C. -  in peripheral and 
ovarian venous samples are shown in Figure 3.32. The levels of the 
hormones found in the peripheral plasma sample from this patient were 
consistent with the EP phase of the menstrual cycle, showing high 
gonadotrophin levels at a time when the steroid hormone levels were 
basal. The steroid hormone levels in the ovarian venous effluent were 
considerably higher than those found in normal cycle patient at the same 
stage of the cycle.
Figure 3.33 shows the hormone levels in the plasma samples from 
the peripheral and both ovarian veins in patient A.W. The levels of 
hormones observed in the samples from this patient were consistent with 
her being in the MS phase of the cycle. This was confirmed by the 
finding of a small corpus luteum on both macroscopic and microscopic 
examination of the ovaries. This corpus luteum was present in the same 
ovary as that containing the large retention cyst, described earlier. It is 
of interest that the levels of 170HP, T and DHT in A.W. were greater 
in the vein draining the contralateral ovary than in the vein draining the 
active ovary.
The levels of hormones in peripheral and ovarian venous samples 
in patient C.E. are shown in Figure 3.34. Although this patient was 
sampled on day twenty four of the cycle the levels of progesterone show 
that this was an anovulatory cycle. Macroscopic examination of the 
ovaries of this patient showed the presence of numerous atretic follicles
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particularly in the left ovary. Presumably the atretic follicles were 
responsible for the increased levels of A, OE^ and 170HP found in the 
venous plasma draining the left ovary. The right ovary of this patient 
contained the retention cyst described earlier.
The levels of steroid hormones in the retention cyst fluids 
obtained from the three patients -  (i.e. patients A.W. and C.E. who were 
on current contraceptive therapy and patient J.H. who had previously 
been on long term contraceptive therapy) are shown in Figure 3.35. 
Steroid hormone levels in the fluids from these cysts were high. In the 
case of patient J.H- who had ceased contraceptive therapy some months 
prior to sampling, the levels of androgens in the cyst fluid were much 
less than those observed in the other two patients.
ii) EARLY PREGNANCY
Patient M.R. was admitted for hysterectomy because of a history
of irregular bleeding. At laparotomy she was found to be pregnant, the 
uterus being of six weeks size. Following hysterectomy a fetus of six 
weeks size was obseiwed. At laparotomy blood samples were obtained 
from a peripheral vein and the ovarian vein draining the ovary contain­
ing the corpus luteum of pregnancy. Figure 3.36 shows the levels of 
hormones found in the peripheral and ovarian venous plasmas in this 
patient. The assay used for LH in this study did not distinguish between 
LH and HCG and the high levels measured in this patient presumably 
represent the HCG rise associated with early human pregnancy. In the 
peripheral plasma levels of OE^, P, 170HP and prolactin, as well as 
HCG were elevated in this patient compared to levels in patients in the 
MS phase of the cycle. Levels of the same hormones were also elevated 
in plasma from the ovarian vein draining the ovary containing the
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corpus luteum, confirming, that at this stage of pregnancy the ovary is 
very active in producing steroid hormones. The levels of OE^, P and 
170HP in the ovarian vein were not, however, elevated in comparison 
with levels found in venous plasmas draining active ovaries in the MS 
stage of the cycle (cf Figures 3.13, 3.14 and 3.15). Androgen levels (A, 
DHT and T) were neither elevated in the peripheral plasma sample nor 
in the ovarian vein sample in comparison with the levels in similar 
samples from the MS phase (cf Figures 3.16, 3.17 and 3.18); in fact the 
A level in the ovarian vein sample in M.R. was lower than that found in 
similar samples from the MS phase (cf Figure 3.25).
iii) POST-MENOPAUSAL PATIENTS
Two patients who presented for hysterectomy were post­
menopausal. 1) I.McV. aged 55, whose last menstrual period was three 
years before the operation and who was having surgery for post­
menopausal bleeding. Following hysterectomy the ovaries in this patient 
showed the typical picture of post-menopausal small atrophic white 
ovaries. 2) M.McL aged 69 years, who last menstruated twelve years 
previously and was operated on because of swelling of the abdomen. At 
surgery the left ovary contained a 60cm cyst which on histopathological 
examination was shown to be a benign mucus cyst of the ovary. The 
right ovary was a typical small white atrophic post-menopausal ovary.
Figure 3.37 shows the hormone levels in peripheral venous 
plasma and one ovarian vein plasma from I.McV. As expected in a 
post-menopausal patient the gonadotrophin levels were very high whilst 
the levels of all of the steroid hormones were low; the levels of the 
steroids in the ovarian venous plasma samples being less than or equal 
to the peripheral plasma levels for all six steroid hormones.
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The hormone levels in peripheral venous plasma and in ovarian 
venous plasma draining the ovary containing the large cyst in patient 
MMcL. are shown in Figure 3.38. As in the previous post-menopausal 
patient (Figure 3.37) the levels of gonadotrophins were very high. The 
steroid hormone levels in peripheral plasma in M.McL. were low and 
consistent with post-menopause but were in some instances (P, 170HP 
and T) higher than the equivalent values obtained in patient I.McV. In 
patient M.McL., in contrast to the findings in I.McV., the levels of all 
six steroid hormones assayed were higher in the ovarian venous plasma 
sample than in the peripheral vein sample.
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Figure 3.1
Effects of different DCC Contact Times 
on A standard curve
% Bound
5 0 '
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2 0 “
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Figure 3.2
Effects of different DCC Contact Times 
on DHT standard curve
% Bound
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301-
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2 0 -
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Figure 3.3
Effects of different DCC Contact Times 
on T standard curve.
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Figure 3.8
Diagrammatic representative of the idealised 
human menstrual cycle
LH
FOLLICULAR OR
PROLIFERATIVE PHASE
PEAK
1 2 - 3 6  hours Pre-ovulation 
LUTEAL OR 
■ SECRETORY PHASE
V
E P M P L P E S L S
menses m enses
1 5 14
DAY OF MENSTRUAL CYCLE
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Figure 3.9
Key used to depict plasmas from peripheral, active ovarian 
and contralateral ovarian veins and abbreviations to denote 
the six stages of the menstrual cycle 
(The same key and abbreviations are used for the remainder 
of the Figures in this thesis)
PERIPHERAL + S.E.M. (P)
ACTIVE OVARY + S.E.M. (O)
g CONTRALATERAL OVARY + S.E.M. (C)
E P -E arly  
M P -M id  
L P -L ate
}Proliferative
ES-E arly  
M S-M id 
L S-L ate }Secretory
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Figure 3.10
Histograms showing levels (mean + SEM) of FSH in
P, O and C venous plasmas throughout the
normal menstrual cycle
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m lU/m l
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Figure 3.11
Histograms showing levels (mean + SEM) of LH in
f ,  O and C  venous plasmas throughout the
normal menstrual cycle
LH
m lU/ml
EP MP LP
2 0 -
LH
m lU/m l
ES MS LS
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Figure 3.12
Histograms showing levels (mean + SEM) of PRL in
P, O and C venous plasmas throughout the
normal menstrual cycle
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PRL
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Figure 3.13
Histograms showing levels (mean + SEM) of P in
P, O and C venous plasmas throughout the
normal menstrual cycle
ng/ml
4 -
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120  -
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ng/ml
2 0 -
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Figure 3.14
Histograms showing levels (mean + SEM) of 170HP in
P, O and C  venous plasmas throughout the
normal menstrual cycle
170HP
ng/ml
10
MPEP LP
55,9
42.8
170HP
ng/ml
10
MSES LS
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Figure 3.15
Histograms showing levels (mean + SEM) of OE2 in
P, O and C venous plasmas throughout the
normal menstrual cycle
OE2
pg/ml
2000
EP LPMP
pg/ml
2000
ES MS LS
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Figure 3.16
Histograms showing levels (mean + SEM) of A in
P, O and C venous plasmas throughout the
normal menstrual cycle
10
A
ng/ml
MPEP LP
12
A
ng/ml
ES MS LS
146Figure 3.17
Histograms showing levels (mean + SEM) of DHT in
jP, O and C venous plasmas throughout the
normal menstrual cycle
800
DHT
pg/ml
400
EP MP LP
DHT
pg/ml
400
ES MS LS
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Figure 3.18
Histograms showing levels (mean + SEM) of T in
P, O and C venous plasmas throughout the
normal menstrual cycle
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Figure 3,19
Comparision of FSH levels in P and O venous plasmas 
at the six stages of the menstrual cycle
16'
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Figure 3.20
Comparision of LH levels in P  and O venous plasmas 
at the six stages of the menstrual cycle
20  -
LH
mlU/m l
EP MP LP ES MS LS
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Figure 3.21
Comparision of PRL levels in P  and O venous plasmas 
at the six stages of the menstrual cycle
4000-
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Figure 3.22
Comparision of P levels in P and O venous plasmas 
at the six stages of the menstrual cycle
P
ng/ml
4
2 -
13.9
I 88.4
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Figure 3.23
Comparision of 170HP levels in P and O venous plasmas 
at the six stages of the menstrual cycle
10 -
170HP
ng/ml
MPEP LP LSMSES
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Figure 3.24
Comparision of OE2 levels in P and O venous plasmas 
at the six stages of the menstrual cycle
OE2
pg/ml
1000 -
EP MP LP LSMSES
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Figure 3.25
Comparision of A levels in P and O venous plasmas 
at the six stages of the menstrual cycle
fzy) 46.7
10 ;
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ng/ml
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Figure 3.26
Comparision of DHT levels in P and O venous plasmas 
at the six stages of the menstrual cycle
1000
DHT
pg/ml
500
EP MP LP ES MS LS
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Figure 3.27
Comparision of T levels in P and O venous plasmas 
at the six stages of the menstrual cycle
(:B2041
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pg/ml
1000^
500"
EP MP LP ES MS LS
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DISCUSSION
I) Radioimmunoassay -  General
Radioimmunoassays have proliferated and proved to be of 
immense value as methods for measuring many different biological 
compounds and have made it possible for the investigator to achieve 
another dimension in physiological and clinical studies.
At the present time new assays based on these techniques appear 
in almost every issue of the endocrine journals. In the work described in 
this thesis radioimmunoassay was employed for the determination of 
protein and steroid hormones in plasma samples and cyst fluids.
One of the most important considerations in the development of a 
radioimmunoassay is the production of specific antisera for the 
compound to be assayed. This is a particular problem in the field of 
steroids since these hormones are themselves not antigenic. To render 
the steroid antigenic a protein molecule must be linked to the steroid to 
produce a complex which on innoculation into animals elicits the 
formation of antibodies.
An assay method must be validated by determination of preci­
sion, accuracy, and sensitivity, and once established assay conditions 
should be standardised. It is important that these parameters are contin­
ually assessed while the method is in routine use.
Once a viable assay has been established, the biggest problem 
encountered in saturation analyses has traditionally been the presence of 
a methodological blank. Steps must be taken to ensure that the blank 
due to methodological interfering factors is insignificant.
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Specificity of a method is determined by (1) the specificity of the 
antiserum employed and (2) any purification procedures used prior to 
assay. Experience has shown that most specific antibodies were 
produced by conjugating the steroid through a position in the steroid 
nucleus remote from the distinguishing functional groups of the 
compound of interest; e.g. OE^ has been conjugated to bovine serum 
albumin through the “ 3” position (Thomeycroft et al 1970) the “ 17” 
position (Caldwell 1971) and the “6” position of the steroid nucleus 
(Exley, Johnson and Dean 1971). Antisera raised to the 6 -linked conju­
gate are most specific and have been employed in the present study. 
However, Walker, Clark and Wotiz (1973) have shown that specificity 
depends not only on the site of conjugation but also on the immunisa­
tion procedure and the carrier protein. The most specific antiserum 
raised to the antigen would be the one of choice, although a relatively 
non-specific antiserum such as the one conjugated at position “ 17” in 
the case of OE^ may be useful if more than one oestrogen is to be 
measured quantitatively in a single sample of plasma. The oestrogens 
can then be separated chromatographically prior to assay of the different 
fractions.
Once specificity has been achieved the next major problem in 
producing a viable assay is the employment of a suitable method for the 
separation of “free” and “antiserum bound” fractions.
The antisera used for all of the assays described in The 
METHODS section were stable on storage for at least two years at -2 0 “ 
and were not altered by freezing and thawing.
Thimerosal was included in all solutions prepared for radioim­
munoassay containing gelatin to act as an inhibitor of bacterial growth.
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II) Extraction of Steroid Hormones from Biological Fluids
It is not possible to routinely perform steroid radioimmunoassays 
directly upon samples of biological fluid unless the fluid has a very low 
protein content (e.g. Liquor Amnii). In more complex fluids the 
presence of protein creates assay blank problems, and as a result the 
hormones must be extracted using organic solvents. The extracting 
solvents used in the steroid assays employed in this thesis are shown in
the MATERIALS and METHODS section and the efficiencies of the 
extraction are reported in the RESULTS section -  Table 3.1.
These results showed that OE^ and 170HP were extracted quanti­
tatively with diethyl ether and P quantitatively with a mixture of petro­
leum ether/ethanol (15/1). In the assays for these hormones extractions 
were assumed to be 100% and no corrections were made. Testosterone 
and DHT were also extracted quantitatively with diethyl ether but, 
because the methods employed a chromatographic purification, internal 
radioactive standards were added to each plasma and individual samples 
were corrected for their own recovery. Androstenedione extraction was 
initially a problem. Quantitative recoveries were obtained using diethyl 
ether but some component(s) of the ether caused blank problems with 
the antiserum used for A radioimmunoassay. As a result a compromise 
was reached and hexane (67-70°) was used for A extraction. This 
solvent gave no blank problem and reproducibly extracted A but only 
with an efficiency of 80%. All A results were corrected for this recovery 
of 80%.
Thus good and reproducible extractions of all steroids assayed in 
this study were obtained and the results presented take into account any 
losses where they occurred. More details of the extraction of the C.19 
androgens, in the new assays developed in this study are discussed later.
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III) Radioimmunoassay -  Specific points applied to new assays in this 
study
(1) SEPARATION OF FREE AND ANTISERUM BOUND 
STEROIDS
A wide variety of techniques has been employed for the separation 
of free and bound fractions in steroid assays including charcoal (Miller 
1957), ammonium sulphate (Mayes and Nugent 1968), florisil (Murphy 
1967), fullers earth (Murphy 1967) and DCC (Herbert, et al 1965).
The addition of gelatin solution prior to charcoal precipitation has 
been used by several workers (e.g. Wu and Lundy 1971). It is conceiva­
bly useful, in assays employing protein precipitation as a method of 
separation of free and bound hormones, since addition of extra protein 
may increase the precipitation of very small amounts of protein present 
in the assay system.
When DCC is used as the method of choice careful attention must 
be paid to the contact time of the DCC with the contents of the 
antigen-antibody incubation mixture, to ensure that all non-specific 
binding has been removed and that significant stripping does not occur. 
Figure 3.1 shows the standard curve obtained for A with different DCC 
contact times of 0, 10, and 20 minutes. Significant stripping occurred 
prior to 10 minutes followed by a plateau where further significant 
reduction in the percentage bound did not occur. Presumably during the 
inital period non-specific weakly bound hormone was being stripped off 
protein by the DCC. When the plateau occurred this process was 
complete. A contact time of 10 minutes was therefore utilised for the A 
assay, this 10 minutes being timed from the addition of DCC to the last 
tube thus ensuring that the 10 minutes was a minimum figure.
In the case of the radioimmunoassays for DHT and T the ideal
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DCC contact times were 20 minutes and 10 minutes respectively 
(Figures 3.2 and 3.3), the timing again being started from the moment of 
addition of DCC to the last tube to ensure that the time stated was 
minimal.
For steroids no method of separation of free and bound fractions 
is absolute but the important parameter for these assays is reproducibi­
lity. In all assays described in this thesis “no As points” were included 
with the standard curve to ensure that the separation of free and bound 
(i.e. the absorption of the free) was reproducible. Charcoal concentra­
tions were used which reproducibly absorbed more than 90% of the free 
fractions.
(2) RADIOIMMUNOASSAY OF A
(i) Specificity
Androstenedione levels in plasma and cyst fluids studied in this 
thesis were determined by radioimmunoassays using an antiserum raised 
to A-7-oxo-bovine serum albumin (Weinstein et al 1972).
Cross-reaction data provided by Miles Veda Ltd. showed signifi­
cant cross-reaction with only 5a androstenedione and epiandrosterone. 
These compounds are reduction products of A and are either further 
metabolised and/or conjugated rapidly for their removal from the circu­
lation. Significant levels of these in their unconjugated form have not 
been reported in human plasma. No significant cross-reaction was 
observed with other major C.19 androgens -  T, DHT and dehydroisoan- 
drosterone. This antiserum is therefore suitable for use in a specific 
radioimmunoassay for A without chromatography. To confirm this, 
samples from the same pool of mixed plasma were assayed employing
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methods with and without chromatography. Table 3.II shows the results 
of this experiment; no significant difference being observed between the 
results obtained with the two techniques. Indeed, if anything, the results 
from the method employing chromatographic purification were more 
variable than those obtained using the direct method. This was presu­
mably a function of the additional manipulations required in the 
chromatographic method. As a result of these findings, in this study, A 
was assayed, using an antisemm raised to A-7-oxo-bovine serum 
albumin without chromatography.
(ii) Extraction
Androstenedione was extracted from the samples as described in 
the RESULTS. Hexane was used as the extracting solvent for A 
because in preliminary experiments extraction with diethyl ether, 
although more efficient, resulted in significant methodological blank 
values. Using hexane as the extracting solvent removed this problem. 
Extraction recoveries of 80 ±  1.2% were achieved for A by this method 
(Table 3.1). Since the recovery was so consistent, each sample assayed 
for A was assumed to be extracted with 80% efficiency and the results 
were corrected accordingly.
(iii) Sensitivity
The radioimmunoassay of A had a blank value of 1.4 ±  2.1 
pg/0.05ml of adrenalectomised, ovariectomised plasma. lOpg of 
unlabelled A caused a significant drop in the percentage of labelled 
hormone bound by the antiserum and was significantly different from 
the blank. Therefore, the limit of sensitivity for radioimmunoassay of A 
was lOpg per 0.05ml sample (i.e. 200pg per ml where 0.05ml samples 
were used).
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(iv) Accuracy and Precision
Intra-assay precision and accuracy were determined by assaying 
plasma (adrenalectomised, ovariectomised) to which 20 replicates of each 
of 30pg and 70pg were added. This gave values for accuracy of 107.7% 
and 103.6% and intra-assay precision values of ±  16.4% and ±  9% at 
the 30pg and 70pg level respectively. Precision and accuracy were better 
at 70pg which fell on the more sensitive part of the standard curve. 
Inter-assay precision was ±  8.7% determined on internal quality-control 
plasmas assayed with each batch of samples. These results show that 
the radioimmunoassay method developed and used in this study for A 
was specific, precise, accurate, sensitive and reproducible.
(3) RADIOIMMUNOASSAY DHT AND T
(i) Specificity
Attempts have been made to produce specific antisera for T by 
coupling the steroid to proteins through a number of positions on the 
steroid molecule. Despite using positions which, for other steroids 
containing functional groups similar to T, have produced specific 
antisera only limited success has been achieved . The major problem 
has been the cross-reactivity of DHT with T. Thus, specific antisera 
distinguishing between the two compounds had not been achieved at the 
initiation of this study. Antisera have been raised after coupling T to 
proteins through C atoms 1, 3, 6, 7, 11 and 17 of the modecule (Rao 
and Moore, 1976). The resultant antisera for T showed large cross­
reactions with DHT (mean ca. 48%). Methods employed for measuring 
either DHT or T accurately therefore require a chromatographic step to 
separate the two steroids.
In this study celite partition column chromatography with ethy-
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lene glycol as the stationary phase was employed (cf METHODS 
section). Columns were eluted with benzene/isooctane mixtures -  5/95 
(v/v) followed by 40/60(v/v).
The antiserum used in this study was raised to T -  3 -oxime 
bovine serum albumin conjugate and had a cross-reaction with DHT of 
55%. No significant cross-reaction was obtained with any other major 
androgens (Table 2.II). The cross-reaction with DHT was not regarded 
as a drawback, in the context of this study, since it was desired to 
measure the levels of DHT and as well as T in the samples. Whilst it 
would have been convenient to have had specific antisera for T and 
DHT, which did not cross-react with each other, use was made of the 
cross-reaction of the T-3-oxim e bovine se mm albumin antiserum to 
assay both hormones. A method was therefore designed to isolate from 
plasmas extracts of both T and DHT with no cross contamination. 
After the initiation of the work reported in this study Rao and Moore 
(1976) described the production of specific antisera for both T and DHT 
using conjugates linked through position 15; such specific antisera were 
not available for use in this study.
Where specific antisera are not available radioimmunoassay may 
be rendered specific by purification, of the material to be assayed, by 
separation from any cross-reacting substances. The most common 
separation technique employed is chromatography. In the experience of 
our labOratoi'y the most suitable type of chromatography for inclusion in 
a routine radioimmunoassay is one which (a) does not introduce metho­
dological interfering factors; (b) gives reproducible and quantitative 
recoveries; (c) employs chromatographic material which may be reused 
and (d) can be performed rapidly without complicating the assay method 
unduly. For the purposes of separating T and DHT we were unable to
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find a method which satisfied all of the above criteria. The method 
which was employed in this study was a compromise which fulfilled 
criteria (a) (b) and (c) above, but employed fairly large volumes of 
solvents and could not justifiably be described as rapid. Each chromato­
graphic run lasted 40 minutes and 5 columns were the maximum 
number that one operator could handle at a time.
Chromatographic separations of DHT and T using celite have 
been described by other workers on much smaller columns (Abraham, 
1974)., In the experience of this author such chromatography on 
“Pasteur pipette” type columns led to considerable cross-contamination 
between the DHT and T fractions. Chromatographic separation was 
therefore performed in this study, as described in the METHODS, using 
bigger columns (19cm x 0.75cm) and larger eluting volumes of solvents 
(20ml DHT ; 15ml T).
This chromatography gave good and reproducible recoveries of 
DHT (79% ±  5.3%) and T (90% ±  7.5%) (Table 3.III). The recovery 
for DHT was slightly lower than that for T, because a conservative cut 
was taken of the DHT fraction to (a) limit the volume to 20 ml and (b) 
ensure, even if column variability occurred that there was no possibility 
of cross-contamination with T.
(ii) Extraction
Even allowing for those losses, associated with chromatography, 
the overall recoveries through the extraction and purification procedures 
were 69% for DHT and 75% for T (Table 3.IV). Although, these reco­
veries were, in hindsight, reproducible, internal standards (of both DHT 
and T) were added to each sample and the individual recoveries for the 
two hormones were used for correction purposes.
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Prepared celite columns for chromatography were reused for up to 
12 runs in one day without any detectable deterioration in the separation 
or increase in the column blanks. Although large volumes of solvents 
were used this did not introduce a significant blank provided all solvents 
were distilled immediately prior to use.
The isolated DHT and T fractions were assayed separately using 
the same antiserum but the radioligand being DHT or T depending 
upon which hormone was being assayed.
(iii) Sensitivity
The radioimmunoassays for DHT and T gave blank values for 
0.05ml of ovariectomised, adrenalectomised plasma of 1.97pg ±  .36pg 
(S.D.; n = 30) and 4.3pg ±  3. Ipg (S.D.; n = 30) respectively. The limit 
of sensitivity was 10 pg for both hormones.
(iv) Accuracy and Precision
Intra-assay variations of DHT and T were computed from assays 
of 10 replicate standards of 50pg and lOOpg of each hormone added to 
adrenalectomised, ovariectomised plasma. These gave accuracies at the 
50pg and lOOpg levels respectively for DHT of 102% ±  12.2% (S.D.) 
and 100.5% ±  11.6% (S.D.) and for T of 112.6% ±  7.4% (S.D.) and 
101.3% ±  8.4% (S.D). Intra-assay precision values from the same exper­
iment were ±  12% and ±  11.6% for DHT and ±  6.6% and ±  8.2% for 
T at the 50pg and lOOpg levels respectively. Values for inter-assay 
precision determined by analysing the data from quality control samples 
assayed with each assay were ±  12.04% and ±  14.68% for DHT and T 
respectively.
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These figures for validation of the assays demonstrate that speci­
fic, accurate, precise, sensitive and reproducible assays were developed 
for both DHT and T.
(4) RADIOIMMUNOASSAYS OF OTHER HORMONES 
ASSAYED IN THIS STUDY
Progesterone, 170H P and OE^ levels in samples were measured 
using radioimmunoassay employing the routine procedures existing in 
the Department of Obstetrics and Gynaecology. Validation of the speci­
ficity, sensitivity, accuracy and precision compare favourably with other 
methods currently available.(Table 3.VII). The assays for FSH, LH and 
PRL which were performed for us in other laboratories also employed 
well validated assay techniques.
IV) Levels of Hormones in Peripheral Plasma Samples 
from Normally Menstruating Volunteers
( 1 ) LEVELS OF C. 19 ANDROGENS
(i) Androstenedione
A specific, sensitive, accurate, precise and reproducible radioim­
munoassay was developed for A. Using this assay, levels were deter­
mined in serial daily plasma samples from seven volunteers. These 
volunteers had apparently normal, regular menstrual cycles and fulfilled 
the criteria for normal cycles described in the MATERIALS section. 
Figure 3.4 shows the mean values of A ±  SEM in these seven cycles. 
The mean levels of A were between Ing and 2ng per ml and showed a 
rise at mid-cycle to an early secretory phase peak (2.3ng/ml; day +2). 
All previously published data for A levels in the normal menstrual cycle 
have employed chromatographic purification steps; alumina columns 
(Judd and Yen 1973), celite columns (Abraham 1974; Baird et al 1974;
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Guerrero et al 1976) and paper chromatography (Frolich, Brand and van 
Hall 1976). Employing the more specific antiserum used in this study 
similar values to those reported by all of these authors were obtained 
without chromatography. A degree of controversy has existed with 
regard to the occurrence of peak levels of A in normal menstrual cycles. 
Some authors have reported significant luteal peaks of this hormone 
(Guererro et al 1976) whilst Abraham (1974) described a distinct peak 
on the day of the LH peak and others described elevated levels around 
the time of ovulation, i.e., in the late follicular and early luteal phases 
(Judd and Yen 1973; Baird et al 1974; Frolich et al 1976). In this study 
peak levels of A were observed in the early luteal phase, (day +2, 48 
hours post LH peak) probably just after ovulation. However, in this 
study, these elevated values were not significantly higher than the levels 
immediately proceeding or succeeding them. Perhaps the situation was 
best described by Judd and Yen (1973) in the first publication of serial 
levels of A in normally menstruating women. These authors showed 
profiles for six individual cycles with rises in all patients, which did not 
always occur at the same stage in relationship to the LH peak. Such 
findings would explain the variability of the conclusions drawn by differ­
ent authors and also the lack of statistical significance of the peaks which 
were found in this and other studies (Judd and Yen 1973). Where signi­
ficant elevation was observed this might have been a result of a fortui­
tous choice of patients. In this study the levels of A found during 
menses (early follicular phase) were lower than those found later in the 
cycle when active growing follicles or corpora lutea would have been 
present in the ovaries.
(ii) Dihydrotestosterone
Dihydrotestosterone levels determined in daily peripheral venous 
samples from normally menstruating women in this study showed mean
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values ranging from lOOpg/ml to 173pg/ml. These levels were very 
similar to those previously reported for DHT in the normal menstrual 
cycle (Abraham 1974), but were slightly lower than those of Guerrero et 
al (1976). The scatter of the latter authors’ results would however 
include the values obtained in this study. Guerrero et al (1976) found 
no fluctuation of DHT levels during the menstrual cycles and Abraham 
(1974) drew similar conclusions although in the latter study the levels 
rose (but not significantly) around the LH peak. In the present study, a 
more distinct elevation was observed around mid-cycle for DHT than 
has been described previously (Figure 3.5). This rise, although not signi­
ficant, occurred in all patients. Again, the lack of significance might be 
related to patient variability with regard tb the actual days of the peak 
values.
The conclusions of Ito and Horton (1971), that A is a major 
precursor of plasma DHT in adult females, would, together with the 
previous discussion of increased A levels at mid-cycle, lend evidence to 
support the findings in this study, that DHT levels rose at mid-cycle. 
The fact that the A peak day varied between individuals (Judd and Yen 
1973) would, if this is the pre-hormone for DHT, mean a similar varia­
bility would be expected for DHT, thus explaining the lack of a signifi­
cant rise, in this study and the apparent constancy of the levels described 
by Abraham (1974) and Guerrero et al (1976). Results reported by 
Coyotupa, Parlow and Abraham (1972) which indicated the possibility 
of a cyclical pattern for plasma DHT, in women, is in agreement with 
the present observations.
(iii) Testosterone
Testosterone levels have been determined previously throughout 
normal menstrual cycles by a number of authors including Judd and
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Yen (1973), Dupon, Hosseinian and Kim (1973), Abraham (1974), 
Tyler, Newton and Collins (1975), Guerrero et al (1976) and Frolich et 
al (1976). These previous workers found mean levels of T of between 
150pg/ml and 500pg/ml, and some controversy existed with regard to 
the pattern of levels throughout the cycle. In the present study mean 
levels of T (Figure 3.6) throughout the cycle ranged from 172pg/ml to 
579pg/ml,; similar to the previously published data. A significant rise 
in the levels of T occurred at mid-cycle with maximal values being 
obtained on the day of the LH peak and the day following (day +1). The 
mid-cycle rise was followed by a fall and thereafter a secondary peak 
was observed in the late luteal phase (day +14). The presence of a 
mid-cycle rise in T levels has been observed by most workers -  Judd and 
Yen (1973)., Abraham (1974)., Frolich et al (1976) and Guerrero et al 
(1976). Dupon et al (1973) and Tyler et al (1975) did not find a 
mid-cycle rise and in both of those studies mean levels were constant 
throughout the cycle. The latter group, however, observed a mid-cycle 
peak in three patients out of nine when they were examined individual­
ly. The finding of patient variability, by Tyler and his colleagues, 
confirmed similar earlier findings by Judd and Yen (1973) and again 
suggests a possible explanation for the inconsistencies reported by the 
different authors. In the present study a mid-cycle rise occurred and a 
secondary peak was observed in the late luteal phase (Figure 3.6) in all 
seven cycles studied. Abraham (1974) also reported a late luteal rise in 
mean values whilst Tyler et al (1975) observed luteal phase rises in two 
of their nine patients but did not indicate the exact timing of those 
peaks. The latter authors further complicated the picture with regard to 
T patterns in “mean cycles” by showing that the levels varied during the 
day in non-pregnant women. As a result, time of sampling might also 
affect the patterns obtained.
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(2) PROLACTIN
Levels of PRL in peripheral samples from normally menstruating 
volunteers throughout the menstrual cycle are shown in Figure 3.7 The 
levels rose, from day -1  to reach peak values on day 0.
During the luteal phase a secondary rise was observed on days 
+ 11 and +12. Neither of these rises were statistically significant peaks but 
all seven cycles showed this trend. These rises in PRL levels at 
mid-cycle and in the late luteal phase were in agreement with previously 
published data from Franchimont et al (1976) but were contrary to the 
observations of McNeilly and Chard (1974) who found no difference in 
PRL levels throughout the cycle.
The occurrence of rises in PRL levels at mid-cycle and in the late 
luteal phase is not surprising since these are the times of the cycle when 
OE^ levels are maximal and it is well established that the output of PRL 
by the lactotrophs is stimulated by oestrogen (Robyn and Vekemans, 
1976).
(3) LH, FSH, OE^, P AND 170HP
The levels of the above hormones estimated in daily plasma 
samples throughout the menstrual cycle from normally menstruating 
volunteers confirmed our previously published results ( (cf figures 1.4 to 
1.8). These findings confirmed that these normally menstruating 
volunteers did indeed have “normal” cycles.
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V) Levels of Hormones in Peripheral and Ovarian venous Plasmas
obtained from Patients at Hysterectomy
(1) DATING OF THE STAGE OF THE MENSTRUAL CYCLE IN
PATIENTS SAMPLED AT HYSTERECTOMY
One of the major criticisms of previous studies of ovarian venous 
levels of hormones has been, apart from the small numbers of patients 
studied, the lack of sufficient information regarding the stage of the 
menstrual cycle. No one parameter is sufficient to accurately date the 
stage of the cycle (e.g. Calabresi et al 1976) and this is particularly true 
in women who are attending for surgery because of some Gynaecological 
complaint.
In this study, therefore, a great effort was made to attempt to 
determine accurately the stage of the menstrual cycle.
As a result reference was made to as many as possible of the 
parameters listed below and the stage of the cycle was assessed from a 
consensus of all of the data available (Tables 3 VIII and 3 Villa),
Even on the basis of all of this information several patients had to 
be omitted from the study because the stage of the menstrual cycle could 
not be adequately assessed.
The following parameters were used to date the stage of the 
menstrual cycle.
(i) Menstrual History:
The menses or menstruation occurs at about monthly intervals. 
The first day of the menstrual loss denotes the beginning of the cycle. In 
the classical case of the normal twentyeight day menstrual cycle the
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proliferative phase lasts for fourteen days and ovulation takes place at 
the end of this. Following ovulation the subsequent fourteen days are 
referred to as the secretory phase which lasts for at least thirteen days 
unless the luteal phase is deficient. Where the menstrual cycle is unduly 
prolonged, it therefore represents an extended proliferative phase. Refer­
ence to the regularity of the patients cycle and the date of the last 
menstrual period therefore gave an indication of the stage of the cycle in 
individual patients.
(ii) Macroscopic Examination of the Ovaries.
At laparotomy of cases involved in this study the ovaries were 
examined in detail for evidence of growing follicles and/or corpora lutea, 
thereby identifying the active ovary. Follicles smaller than 5mm in 
diameter were often seen in both ovaries in the EP stage; medium sized 
follicles (5mm to 15mm in diameter) were observed in the MP stage and 
bigger follicles with thin walls indicating impending rupture were asso­
ciated with the LP stage. The presence of a fresh corpus luteum was 
usually identifiable by haemorrhages on the surface of the active ovary 
(ES). When mature corpora lutea were present the stage of the luteal 
phase was determined by reference to other parameters.
(iii) Microscopic Examination of the Ovary
Ovaries if removed were serially sectioned for evidence of follicles, 
corpora lutea and corpora albicantes in an attempt to further date the 
stage of the menstrual cycle.
(iv) Histological Study of the Endometrium
Samples for endometrial biopsies were transported to the Patho­
logy Department for immediate analysis since prolonged fixation and/or
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delay in immersing specimens in the fixative make precise dating of the 
endometrium difficult. The classical cellular changes in the endom­
etrium as described by Noyes, Hertig and Rock (1950) were used as a 
reference for dating with regard to each patient’s stage of the menstrual 
cycle.
(v) Levels of Hormones in Peripheral Plasma Samples
Mid-cycle peaks of the gonadotrophins LH and FSH (to a lesser 
degree) are classical reference points in the normal cycle. The LH surge 
(see INTRODUCTION section) occurs when the mature follicle is ready 
to rupture and ovulate. Thus high levels of LH immediately precede 
ovulation. Elevated levels of FSH are associated with the period 
immediately prior to and during menses when a group of follicles are 
being stimulated to grow. Thus high levels of FSH in the presence of a 
less distinct rise in LH than occurs at mid-cycle are indicative of the EP 
stage.
During the remainder of the proliferative phase OE^ is secreted in 
inereasing amounts culminating in the well established peak which 
causes the positive feedback release of LH. Throughout the proliferative 
phase P levels remain basal.
Following lutéinisation and ovulation the corpus luteum secretes 
quantities of P together 
few days prior to the LH peak.
large qua ti with similar levels of OE^ to those found a
High levels of OE^ alone are found in the MP and LP phases and 
elevated levels of both P and OE^ are associated with the secretory 
phase. From the actual levels of P it is possible to approximately
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allocate patients to the stages of the secretory phase -  ES (>  Ing/ml to 
< 5ng/ml); MS (> 5ng/ml) and LS (<  5ng/ml) together with levels of OE^ 
which are sub-maximal. The distinction between ES and LS on 
hormonal grounds alone is difficult and requires information from other 
parameters such as those described above -  V) (I) (i) to V) (1) (iv).
The levels of LH, FSH, OE^ and P in peripheral plasma samples 
from patients in this study were used mainly to confirm the stage of 
cycle assessed by the other parameters. However, in a few cases where 
the information from V) (1) (i) to V) (1) (iv) was incomplete or 
inconclusive hormone levels were used to date the stage of the cycle.
(2) OVARIAN VENOUS SAMPLING
Ovarian venous effluents were collected in this study from 
patients undergoing hysterectomy for conditions which did not affect 
their reproductive function (see MATERIALS and METHODS section).
Informed consent was obtained to collect concurrently bilateral 
ovarian and peripheral venous plasma samples. The vein draining the 
ovary which appeared more active was sampled first concurrently with 
an antecubital vein; the contralateral ovarian vein was sampled 
immediately thereafter. Where success in obtaining a sample was not 
immediate, only ovarian venous effluents draining active ovaries were 
collected to avoid prolonging operating time unduly. The ovarian vein 
leaving the hilum of the ovary on each side was selected in all cases. 
Variability of the pattern and calibre of the venation in the mesovarium 
posed difficulties in some cases. Previous workers (Horton, Romanoff 
and Walker 1966; Mikhail, 1970) overcame such problems by severing 
the veins in the mesovarium and collecting the pooled blood released
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thereon. Blood samples collected in this way may not be pure venous 
samples but may be contaminated with arterial blood.
With progress of the study difficulties in blood collection became 
minimal presumably due to the increasing expertise of the operator.
Best results were achieved when the following guidelines were 
adhered to;-
(a) The abdomen, after opening, was lightly packed, to facilitate 
filling of the pampiniform plexus whilst still allowing sufficient room for 
manoeuvrability.
(b) The operation table was in a slight Trendelenberg position to 
bring the operating area into a more open view.
(c) A pair of Babcock forceps were applied at each pole of the 
ovary to permit easy handling of the ovary without any squeezing. This 
ensured that the ovarian venous effluent was collected under as physiolo­
gical conditions as possible.
(d) ‘25’ guage needles were used for sampling. However, in a few 
cases, where the venation was tortuous and grossly distended, ‘23’ guage 
needles were found to be more suitable to facilitate aspiration without 
leakage between the needle and the venous wall.
(e) Small syringes were used (5ml or less). This allowed easy 
handling and prevented excessive suction, which might have collapsed 
the venous wall.
(f) Suction was applied intermittently allowing the vessels to refill in 
between.
Many previous authors have avoided sampling too close to the 
ovary for fear of associated bleeding. In the author’s experience digital 
pressure, or compression with a warm pad for two minutes on the
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puncture sites was sufficient to prevent bleeding or haematoma forma­
tion. If either complication had occurred it would have been necessary 
to sacrifice the ovary. No such occasion occurred in this study.
Using the methods described in this thesis good samples of pure 
ovarian venous plasmas were obtained with minimal complications.
(3) SIGNIFICANCE OF HORMONE LEVELS IN OVARIAN
VENOUS EFFLUENTS
The design of the studies reported in this thesis assumed that 
comparison of the levels of hormones in veins draining ovaries (active or 
contralateral) with levels in corresponding peripheral plasmas would give 
information regarding the ovarian production of hormones. Two 
separate experiments were conducted in an attempt to confirm that this 
was the case. Firstly the levels of hormones were compared in one 
patient in peripheral plasma and in plasmas from the vein draining and 
the artery supplying the active ovary and secondly the effects of bilateral 
oophorectomy on the peripheral plasma levels of hormones over a 
num ber of days were examined.
The patients in whom peripheral and ovarian venous and arterial 
samples were compared was in the LP stage of the cycle. The results 
(Table 3XXVIII) showed that whereas the levels of all six steroid 
hormones were identical in the peripheral and ovarian arterial plasmas 
they were much higher in the ovarian venous plasma. Since the ovarian 
arterial and venous samples were virtually collected simultaneously the 
differences can only be explained by secretion of the hormones by the 
ovary. Secretion of steroid hormones by ovaries was confirmed by 
examination of the effects of bilateral oophorectomy in a patient in the
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EP stage (Table 3.XXIX). Peripheral plasma samples were collected 
before and for six successive days after ovariectomy.
Even though this patient was at the least active stage of the cycle 
an immediate (by 1 day) reduction was observed, in the levels of all six 
steroids measured, after ovariectomy. These effects of bilateral oophor­
ectomy have now been confirmed in a much larger series of patients 
(Barlow et al, 1981).
The results of these two studies were interpreted as evidence that 
peripheral-ovarian venous plasma differences in the levels of steriod 
hormones were indicative of hormone production by the ovaries. Due 
to the inherent risks associated with arterial sampling ovarian arterial 
plasma samples were not collected from other patients.
(4) HORMONE LEVELS IN PERIPHERAL AND OVARIAN
VENOUS PLASMAS OBTAINED FROM NORMALLY
CYCLING WOMEN AT HYSTERECTOMY
Prior to the initiation of the studies presented in this thesis little 
information was available with regard to hormone levels in ovarian 
venous plasma. Isolated findings, usually from only a few patients, had 
been reported by several workers (Horton et al 1966; Rivarola et al 
1967; Gandy and Peterson 1968; Mikhail 1970). Many of these samples 
were obtained from patients with polycystic ovarian disease who did not 
have normal cycles. It was difficult to correlate the findings of these 
studies with in vitro work on steroid biosynthesis, largely because, 
in most instances, no close attention was paid by the authors to the stage 
of the menstrual cycle of the patients at the time of sampling. Further­
more, there was considerable doubt in some instances as to the purity of 
the samples with regard to ovarian effluent. Often, where details of the
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exact procedures used for sampling were given, it seemed likely that the 
samples collected might be contaminated with uterine effluent. In only a 
few cases did reports describe collection of blood from both ovarian 
veins thus allowing comparison of hormone levels in the ‘active’ ovary 
(containing the preovulatory follicle or corpus luteum) with the contrala­
teral, ‘inactive’, ovary to ascribe the production of particular hormones 
to specific ovarian structures. Mikhail (1970) described steroid produc­
tion from both ovaries in 7 normal patients, 6 of whom were in the 
luteal phase of the cycle. In M ikhail’s study the stage of the menstrual 
cycle was well documented but his method of blood collection was not 
ideal since by his techniques he might possibly also have collected 
ovarian arterial blood thus obtaining lower results than the true 
hormone levels in the ovarian venous effluent.
The study described in this thesis was designed to collect 
peripheral and ovarian venous blood plasmas from patients who had 
normal reproductive function. Where possible venous blood draining 
both ovaries was collected. The number of patients in whom bilateral 
blood samples were collected was limited by a desire that these experi­
mental techniques should not unduly prolong the surgery. In all patients 
the stage of the menstrual cycle was critically assessed by use of as many 
parameters as possible (Tables 3.VIII and 3.Villa) and the patients were 
assigned to each of the 6 groups -  EP, MP, LP, ES, MS and LS -  thus 
enabling a composite menstrual cycle to be constructed. Sufficient 
contralateral ovarian vein samples were obtained to ensure that conclu­
sions could be drawn in both proliferative and secretory phases as to the 
secretory activity of the ‘active’ and ‘inactive’ ovaries. The composite 
menstrual cycle levels were compared with those in peripheral venous 
samples obtained from young healthy normally menstruating volunteers.
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During the progress of the work described in this thesis a number 
of papers have been published which have produced results from 
normally menstruating women with better controlled sampling of 
ovarian venous plasmas and more rigorous assessment of the stage of the 
menstmal cycle than in the previous publications. In most cases, largely 
due to the problems of the human as an experimental animal, patient 
numbers have been small. Baird et al (1974) studied A levels in 10 
normally menstruating patients (3, EP; 1, MP; 2, LP; 2, ES; 1, MS; 1, 
ES); de Jong, Baird and Van der Molen (1974) measured A, OE^, OEj, 
T, P and dehydroisoandrosterone and its sulphate in 4 normally 
menstruating patients (1 menstruating, 1 MP and 2MS); Baird and Eraser 
(1974) reported levels of OEj  ^ and OE^ in 11 patients (2, EP; 3, LP; 2, 
ES; 3, MS; 1, LS); McNatty et al (1976) reported levels of O E^ OE^, A 
and T in 11 normally menstruating women (3 early follicular, 4 late 
follicular and 4 luteal) and Calabresi et al (1976) measured OE^, P, A, T 
and DHT in 15 normally cycling patients who were all in the luteal 
phase. In a later publication an extension of the work of Calabresi and 
his colleagues was published (Serio et al 1976) in which in addition to 
the 15 luteal phase patients 7 proliferative phase patients (3, EP; 2,MP; 
2, LP) were also studied and as well as the above levels those of OE^ and 
dehydroisoandrosterone were also reported. In these two publications, 
however, (Calabresi et al 1976; Serio et al 1976) the stage of the 
menstrual cycle was assessed only from the menstrual history and 
macroscopic examination of the ovaries. Much more recently Aedo et al 
(1980 a; 1980 b) have published two papers regarding the contributions 
of the Graafian follicle (Aedo et al 1980 a) and the corpus luteum (Aedo 
et al 1980 b) to ovarian steroid secretion in normally menstruating 
women. These authors paid very strict attention to ovarian venous 
sampling and dating of the stages of the cycle but have only to date 
reported results from 9 patients in each of the LP and ES phases.
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The results presented in this thesis are discussed under 3 separate 
headings:-
(a) a comparison of the mean hormone levels throughout the 
menstrual cycle in plasma from the peripheral circulation with those in 
plasmas draining both ‘active’ and ‘inactive’ ovaries;
(b) a comparison of hormone levels in peripheral plasmas, contrala­
teral ovarian venous plasmas and active ovarian venous plasmas from 
patients in whom all 3 sites were sampled and
(c) with respect to their contribution to our understanding of 
hormone production by the human ovary.
(i) Hormone Levels in Ovarian Venous Effluents and in Peripheral 
Plasmas in Normally Cycling Women
The results from the whole group of women are discussed below 
under the nine individual hormones labelled A to I as in the RESULTS 
section.
(A) FSH
The levels of FSH found in the peripheral and ovarian venous 
samples -  both active and contralateral -  were not significantly different 
from each other. The levels, as expected from serial samples determined 
in normal cycles (Coutts 1976) were high in the early proliferative phase 
and were lower during the rest of the cycle (Figure 3.10). No evidence 
was obtained, from any patient, of a significant drop in the levels of FSH 
in the ovarian venous effluent compared to the levels in the peripheral 
samples (Tables 3.IX, 3.X). Such a drop might have been expected if 
FSH stimulates follicular growth after being bound to receptors in the 
growing follicles (McNatty et al 1975). Since the secretion of gonad­
otrophins is episodic (Boyer et al 1972) presumably the techniques of
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blood sampling and/or radioimmunoassay of FSH were not sufficiently 
well designed and/or sensitive enough to observe the removal of FSH 
from the peripheral circulation during passage through the active ovary.
(B) LH
The levels of LH in the plasma samples were highest in the late 
proliferative stage of the cycle, presumably as a result of release of LH in 
response to the positive feedback effect of OE^ on the hypothalamus 
(Yussman and Taymor 1970). The LH levels in the LP stage were 
variable, presumably because of the design of an LP group; some 
patients would be included just prior to the LH surge whilst others 
would be sampled during the time of peak release. No significant differ­
ence was observed between the levels of LH in peripheral and ovarian 
venous samples. Failure to detect a peripheral /ovarian gradient in LH 
values caused by binding of LH to mature follicles was again presumably 
a function of a combination of complicating factors such as, episodic 
secretion of LH and/or the inability of the assay to pick up minor 
fluctuations in LH levels.
(C) PROLACTIN
The levels of PRL observed in samples obtained at surgery were 
much higher (5 times) than those observed in peripheral venous samples 
from normally menstruating volunteers (Figure 3.7). This was presuma­
bly a response to anaesthesia and/or operative stress in the hysterectomy 
patients. Increases in PRL levels shortly after the induction of anaesthe­
sia have been reported (Robyn et al 1973; Fournier, Desjardins and 
Friesen 1974). W hether this is an actual effect of the anaesthetic or is a 
result of collection of samples under the stress of surgery (Robyn et al 
1976) is unknown and could not be determined since patients were not
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subjected to major surgery without anaesthesia. McNatty et al (1975) 
also observed similar increases in peripheral plasma PRL concentrations 
in samples collected from patients at surgery compared with those of 
matched volunteers. Although the levels of PRL were increased the 
effect seemed to be consistant in individual patients in both ovarian and 
peripheral venous plasma samples. No significant differences were 
observed between the levels of PRL in ovarian and corresponding
peripheral venous plasmas at any stage of the cycle. It was therefore 
impossible to demonstrate that follicles at different stages of the cycle 
bound different amounts of PRL (McNatty et al 1975) but such minor 
differences may have been obscured by the dramatic increases in 
response to stress and/or anaesthesia.
(D) PROGESTERONE
Levels of P found in peripheral plasmas from patients sampled at 
hysterectomy showed the same patterns as are well established in peri­
pheral plasmas from normally menstruating volunteers (Dodson, Coutts 
and Macnaughton 1975); low levels were found in the proliferative phase 
and higher levels in the secretory phase (Figure 3.13). The levels of P 
present in plasma from veins draining active ovaries showed similar 
patterns to those described above but the levels were much higher than 
those in peripheral plasma during the secretory phase (17 times higher at 
MS) (Figure 3.13). These results confirm the conclusions of previous 
workers, Mikhail(1970); de Jong et al (1974), Calabresi et al 1976; 
Lucisano et al 1978, that the major source of secretion of P in the 
human female is the corpus luteum. The levels of P in the ‘active’ 
ovarian veins were significantly higher that those in the peripheral veins 
or the contralateral ovarian veins during the secretory phase (p < .02). 
Progesterone levels in the contralateral ovarian veins were not signifi­
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cantly different from those in peripheral plasma at any stage of the cycle 
thus confirming the conclusions from other studies (Mikhail 1970; 
Calabresi et al 1976; Lucisano et al 1978) that with respect to P synthe­
sis, the contralateral ovary was inactive. These findings are however at 
variance with those of Aedo et al (1980 a; 1980 b) who concluded that P 
was also produced by the contralateral ovary.
Evidence was obtained from both MP and LP samples that 
preovulatory lutéinisation (Dodson et al 1975) occurred. The rise in P, 
prior to ovulation, was found in both peripheral venous samples and 
also plasmas from veins draining active ovaries. This proliferative stage 
progesterone was confirmed as a product of the active ovary since the 
levels in plasmas from veins draining active ovaries were much higher 
than those in the corresponding peripheral venous samples (Table 
3.XV). The P levels in the ‘active’ ovarian venous plasmas were signifi­
cantly higher than peripheral levels at the MP stage of the cycle (p 
<0.05). Mikhail (1970), Lloyd et al (1971), de Jong et al (1974) and 
Serio et al (1976) have reported similar results with higher P levels being 
associated with the active ovarian venous plasma. Aedo et al (1980 a) 
on the other hand provided evidence that P was secreted by both ovaries 
and not only by the one containing the Graafian follicle. Perhaps by 
selecting patients very close to the LH peak when changes are occurring 
in P secretion these last authors introduced such patient variability that 
the contribution of the follicle to P secretion became difficult to assess.
(E) 17a HYDROXY PROGESTERONE
Peripheral plasma levels of 170HP in serial daily samples from 
normally menstruating women showed a rise at about the time of the LH 
peak. In some patients this rise was followed by a nadir whilst in others
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it formed a shoulder on the luteal peak which occurred in all patients 
(Dodson et al 1975). Strott et al (1969) suggested that the mid-cycle rise 
in 170HP was a result of the release of this intermediate on the 
biosynthetic pathway to oestrogen, at the time when the follicle had 
matured and OE^ synthesis was slowing down. Coutts (1976) questioned 
this hypothesis and suggested that the rise in 170HP reflected pre­
ovulatory lutéinisation. The results from the peripheral samples 
obtained at hysterectomy showed similar patterns and levels to those 
from normally menstruating volunteers; maximum levels occurred in the 
LP stage with a secondary rise in MS and LS stages (Tables 3.XVII, 
3.XVIII; Figures 3.14, 3.23). Levels of 170HP in veins draining the 
active ovary were higher than corresponding peripheral levels at all 
stages of the cycle (Figure 3.23) being significantly so at MP. LP and MS 
stages (RESULTS section). The maximum levels of 170HP in the 
active ovarian veins were found in the MS phase where levels of 16 
times those found in peripheral samples were observed (Figure 3.23). 
Mikhail (1970) in his small series, also found very high levels of 170HP 
in the active ovarian vein. The ratio of 170HP in active ovarian 
venous plasm a/170H P in peripheral venous plasma was almost identical 
to that obtained for P levels in the same samples (Figures 3.22) suggest­
ing that the latter hormone was a precursor of the former. In the MP 
and LP stages, levels of 17 OHP in active ovarian venous plasmas were 
of the order of twice those in peripheral plasmas (Figure 3.14). The 
highest levels of 170HP found in the proliferative stage in venous 
samples draining active ovaries were at MP (Figure 3.23). At this same 
stage proliferative levels of OE^ were also maximal (Figure 3.24). These 
findings were not in accord with the suggestion of Strott et al that peak 
levels of 17 OHP were associated with reduced secretion of OE^. The 
increase observed in 170HP levels at mid-cycle in peripheral venous 
samples (Figure 3.14) may well reflect further metabolism of P synthe­
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sised as a result of the early stages of luteinsation (Figure 3.13). The 
findings that 170HP is synthesised by both the Graafian follicle and the 
corpus luteum are in general agreement with the observations of Aedo et 
al (1980 a; 1980 b). Since only a few results were available for 170HP 
levels in plasmas from veins draining contralateral ovaries it was not 
possible to draw definitive conclusions with regard to the synthesis of 
this steroid by the inactive ovary. However, from the few results 
presented the impression was that only in the MS stage might there be 
170HP secretion by the contralateral ovary.
(F) OESTRADIOL
The levels of OE^ found in the peripheral plasma samples 
obtained from women at hysterectomy showed the same biphasic pattern 
which has been described by many workers from normally cycling 
volunteers showing peaks in LP and MS stages (Ross et al 1970; 
Abraham et al 1972; Shaaban and Klopper 1973; Dodson et al 1975). 
The actual levels of OE^ observed from these patients were much lower 
than the equivalent peaks in normal volunteers at the same stages. No 
entirely satisfactory explanation can be given for this finding but the 
patients fitted a much older age group than most volunteers studied and 
also the grouping of the patients into stages of the menstrual cycle may 
well have resulted in slight overlaps causing distribution of the peak 
values obtained. Although these mean levels of OE^ were low they were 
just within 2 S.D.s below the mean values of normal cycle levels (Coutts 
1976) published from our laboratory.
The levels of OE^ in the samples from veins draining active 
ovaries were much higher at all six stages of the cycle than the corre­
sponding levels in peripheral plasma samples, being significantly higher
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at all stages except EP where the significance was borderline (p<0.1). 
Peak active ovarian vein levels of OE^ were found in the MP stage, i.e. 
before peak levels were found in peripheral samples. This was consis­
tent with a nadir occurring prior to ovulation. The LP group would 
presumably have included patients in whom the positive feedback of 
OE^ had been achieved, who were about to rupture their mature follicles 
and in whom levels of OE^ would have decreased.
The secondary peak of OE^ occurred in the MS stage samples 
where the ratio of OE^ in active ovarian veins/OE^ in peripheral veins 
was 16:1 -  a very similar finding to those described for both P and 
170HP above. These results confirmed that the source of the vast 
majority of OE^ in the human female of reproductive age was the active 
ovary (Mikhail 1970; de Jong et al 1974; Baird and Eraser 1974, 1975; 
Serio et al 1976 McNatty et al 1976; Aedo et al 1980 a). The failure of 
Aedo et al 1980 b to observe similar findings during the ES stage of the 
cycle was presumably related to their choice of subjects.
Levels of OE^ in contralateral ovarian veins were also higher than 
their corresponding peripheral levels at all stages of the cycle where 
sufficient contralateral ovarian vein samples were available. Statistical 
assessment showed that the contralateral ovarian venous OE^ levels were 
significantly higher than those in corresponding peripheral venous 
samples (RESULTS section). Increased levels of OE^ in contralateral 
ovarian venous samples have been reported by other workers, usually 
without comment (Mikhail 1970; Baird and Fraser 1974). Baird and 
Fraser (1974) using elegant techniques determined the contribution of 
the active ovai^y to the blood production rate of OE^ and concluded that 
this was > 95% at some stages of the cycle, de Jong et al concurred
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with these findings that the active ovary was the major source of OE^ 
and also concluded from similar blood production studies that although 
the contralateral ovarian vein contained higher OE^ levels than the 
equivalent peripheral venous samples the ‘inactive’ ovary produced an 
insignificant amount of OE^. Calabresi et al (1976), who only examined 
patients in the luteal phase, did not find an increased level of OE^ in the 
contralateral ovarian veins compared to their peripheral samples.
Although the contribution of the contralateral ovary was insignifi­
cant, by comparison with that of the active ovary, the finding that the 
contralateral ovarian vein contained significantly more OE^ than the 
peripheral vein is important in consideration of whether the contralateral 
ovary is ‘inactive’ or not. The results produced by Aedo et al (1980 a; 
1980 b) confirm those of this study showing that the contralateral ovary 
produces OE^.
(G) ANDROSTENEDIONE
The levels of A in peripheral plasmas from women undergoing 
surgery were consistent with these in peripheral plasma samples from 
normally menstruating volunteers (Figure 3.4). Although there was a 
luteal phase rise this was not significant and the levels in the luteal phase 
were no different from those at mid-cycle or during the MP and LP 
stages.
Levels of A in plasmas from veins draining ovaries indicated that 
the major site of A production was the active ovary. The ratio of A 
levels in active ovarian venous plasmas to those in peripheral plasmas 
were 3.8:1 (MP) and 19.5:1 (MS). Thus the major sites of production of 
A by ovaries were the Graafian follicle and the corpus luteum.
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The A levels in venous plasmas draining contralateral ovaries 
were much lower than those in venous plasmas draining active ovaries 
but nevertheless were higher than those in peripheral plasmas -  signifi­
cantly so in the MS phase (p<0.01). Other workers have observed 
production of A by the Graafian follicle (de Jong et al, 1974; Serio et al, 
1976; McNatty et al, 1976) and the corpus luteum (Calabresi et al, 1976; 
McNatty et al, 1976), but some groups have concluded that A is 
produced by both ovaries equally throughout the cycle (Aedo et al, 1980 
a; 1980 b) or during the luteal phase (de Jong et al, 1974). The latter 
author’s conclusions must be related to their small numbers of patients
whilst Aedo and his colleagues by the design of their patient selection 
did not study the situation during either maximal follicular or luteal 
activity.
The results presented here show quite clearly that during both 
proliferative and secretory stages of the cycle the active ovary is a major 
source of A production. In addition small amounts of A are also secret­
ed by the inactive ovary particularly during the MS phase. Presumably 
the ovarian stroma is responsible for this A secretion by the contralateral 
ovary (Rice and Savard, 1966) and the biosynthetic capacity of that 
compartment for production of A is insignificant compared to that of the 
corpus luteum(Savard et al, 1965).
Despite the high levels of A obseiwed in active ovarian venous 
plasmas and the cyclical changes therein the levels found in peripheral 
plasmas (both normal volunteers and patients) were relatively low and 
showed no distinct luteal phase peak. This suggests that rapid metabo­
lism of a large percentage of the ovarian A must occur either in other 
organs or in peripheral tissues. A is a major prehormone for T (Ito and 
Horton, 1971) in women and has also been shown to be converted into
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OEj in many peripheral tissues (Longcope 1971) especially adipose 
tissues (Nimrod and Ryan, 1975).
(H) DIHYDROTESTOSTERONE
The levels and patterns of DHT measured in the peripheral 
plasma of women undergoing hysterectomy (Figure 3.26) were similar to 
those seen in peripheral plasma samples from normally menstruating 
volunteers (Figure 3.5).
Dihydrotestosterone levels in plasmas from veins draining active 
ovaries were higher than those in corresponding peripheral plasma 
samples at all six stages of the menstrual cycle; maximal differential 
being observed in the MS phase when active ovarian vein levels were 6 
times higher than peripheral plasma levels. The presence of 5a reductase 
activity in ovarian tissue ; previously established in vitro (Smith, Ofner 
and Verra, 1974), has been confirmed by these results. Since T, the 
substrate for the reductase enzyme, is largely synthesised from A in 
women (Ito and Horton, 1971) the DHT elevation in the MS phase is 
probably a reflection of the increased A production (Figure 3.25). In 
contrast to the DHT results reported in this thesis Calabresi et al (1976) 
reported no such DHT increase in the venous effluent of the active 
ovary during the luteal phase. Analysis of that author’s data using a 
paired t test revealed, however, that Calabresi’s findings were different 
from his conclusions (DHT > in active ovary than in peripheral plasma; 
p < 0.001)! Serio et al (1976) also showed that during the follicular 
phase DHT levels were higher in active ovarian venous plasmas than in 
contralateral and/or peripheral plasmas but Aedo et al (1980 a; 1980 b) 
who sampled only in the LP and ES stages concluded that the levels of 
DHT were identical in peripheral and both ovarian venous plasmas.
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In the present series DHT levels in contralateral ovarian venous 
plasmas where estimated were identical to or slightly higher than those 
in corresponding peripheral plasmas; the elevations were significant in 
the MS phase when A levels in contralateral plasmas were also signifi­
cantly higher than those in peripheral plasmas.
These results confirm the ability of human ovarian tissue to 
produce DHT and suggest that significant DHT production only occurs 
when production of the precursor A is also increased.
(I) TESTOSTERONE
The profiles of T levels found in peripheral plasmas of women at 
hysterectomy (Figure 3.18) were similar to those determined in normally 
menstruating volunteers(Figure 3.6) showing a peak at mid-cycle and a 
further rise during the luteal phase. The elevation in peripheral plasma 
in the ES phase of the cycle was in agreement with the report of Aedo et 
al(1980 b).
Plasmas obtained from veins draining active ovaries contained 
higher levels of T than did corresponding peripheral plasmas at all 6 
stages of the menstrual cycle, the elevations being significant in MP, MS 
and LS stages.
The highest levels of T in active ovarian venous plasmas were 
found during the LP and MS stages and at both of these stages there 
were great variations in the levels amongst the patients who composed 
the group. The LP peak of T values observed in the active ovarian 
veins (Figure 3.27) was in agreement with the observations during the 
normal menstrual cycle (Figure 3.6) but was different from the pattern
203
observed for A in the active ovarian vein suggesting that if A is the 
major prehormone for T in the human female (Ito and Horton, 1971) 
the extent of the conversion must vary considerably from patient to 
patient. This LP rise in T levels was coincident with a fall in active 
ovarian venous plasma OE^ levels after the follicle had reached maturity 
(Figure 3.24). The levels of T observed might therefore reflect a 
compromise between conversion of the prehormone A and further 
metabolism.
The MS peak of T levels in active ovarian venous plasmas (6 
times higher than peripheral plasma levels) was in agreement with the 
already described MS peaks of both A and DHT and adds credence to 
the suggestion that the rises occurring during the MS phase are due to 
increased synthesis by the corpus luteum of A which functions as a 
prehormone for T which in turn is converted to DHT.
Only very few samples were available for determination of T 
levels in venous plasmas draining contralateral ovaries. In the MS 
phase where a number of samples were available T levels were signifi­
cantly higher in contralateral ovarian venous plasmas than in corre­
sponding peripheral plasmas. Since similar increases in the contralater­
al ovarian venous plasma levels of A and DHT in the MS phase were 
reported earlier these increased levels of T might have been expected 
confirming that the three C. 19 androgen levels in ovarian venous 
plasmas are closely inter-related.
Previous reports have indicated T production in approximately 
equal amounts by both active and inactive ovaries (Mikhail, 1970; de 
Jong et al, 1974; Aedo et al, 1980 a; 1980 b) whilst in agreement with
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the present study Calabresi et al (1976); Serio et al (1976) and McNatty 
et al (1976) showed higher levels of T in the blood emanating from
active ovaries than in that draining contralateral ovaries.
These results show that T is produced by both ovaries but in 
larger amounts by the active ovary. Presumably as described earlier for 
A the ovarian stroma in both ovaries produces T whilst during the times 
of maximal follicular and luteal steroid biosynthesis a further increment 
is added to the output of the active ovary.
(ii) Hormone Levels in Active Ovarian Venous Plasma, Contralateral
Ovarian Venous Plasma and Peripheral Plasma from the same
Patient
Where plasma samples were available from all three venous sites 
-  active ovary, contralateral ovary and peripheral -  Table 3 XXVII 
similar findings were obseiwed to those described above for the mean 
data from all of the patients. The active ovarian venous plasmas were 
associated with significantly elevated levels of P and 170H P at all stages 
except EP but particularly in MS, and of OE^, A and DHT throughout 
the cycle. In the case of T the situation was more variable and less clear 
but the levels in the active ovarian venous plasma were usually higher 
than the corresponding peripheral plasmas. Contralateral ovarian 
venous plasmas were associated with increased levels compared with 
peripheral plasma of OE^ but not of P and 170HP. The levels of C.19 
androgens coming from the contralateral ovarian veins although not 
significantly higher than peripheral plasma levels in this small series of 
patients were higher than the latter and suggestive that the contralateral 
ovary produces small amounts of these C.19 androgens.
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The similarity of the conclusions from these patients who provid­
ed samples from all three venous sites and those from the mean data of 
all of the patients (V 4i) show that it is valid to draw conclusion with 
regard to ovarian production of steroids from the mean data.
(iii) Hormone Production by the Human Ovary
During the normal menstrual cycle the Graafian follicle is primar­
ily responsible for production of OE^ during the MP and LP stages. In 
addition the growing follicle also produces small amounts of P, 170HP, 
A, T and DHT. After ovulation and formation of the corpus luteum 
that structure becomes the main producer of steroids and is responsible 
for secretion of large amounts of P, 170HP and A; for maintaining OE^ 
production at slightly lower levels than during the time of maximal folli­
cular activity and for production of increased levels of DHT and T.
The contralateral ovary is not inactive but produces small 
amounts of OE^ and the three C.19 androgens.
A study such as that presented in this thesis cannot give informa­
tion with regard to which cellular type within the Graafian follicle or the 
corpus luteum is responsible for synthesis of steroid hormones. 
However, present work from a number of laboratories suggest that the 
follicular theca cells are responsible for the biosynthesis of 170HP, C.19 
androgens and some oestrogen during the follicular phase (Gaukroger 
1979) whilst the follicular granulosa cells synthesize P per se and convert 
thecal C.19 androgens to oestrogen (Coutts et al 1981). The luteal 
granulosa cells synthesize P and 170HP whilst theca lutein cells are 
probably responsible for production of C.19 androgens and oestrogens 
(Macnaughton et al 1981).
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The site of production of OE^ and androgens by the contralateral 
ovary requires further elucidation but is most probably the combined 
efforts of thecal cells of small follicles and ovarian stroma.
(5) HORMONE LEVELS IN PERIPHERAL PLASMAS AND
OVARIAN FLUIDS OBTAINED AT HYSTERECTOMY
FROM PATIENTS WHO HAD ABNORMAL CYCLES
(i) Polycystic Ovarian Disease
On macroscopic and microscopic examination of the ovaries after 
hysterectomy and blood sampling two patients were found to have had 
polycystic ovarian disease. Unlike many patients with polycystic 
ovarian disease (Van Look 1981) these patients showed ovulatory cycles 
and were assessed as being in the MS and LS phases respectively. In 
patients with polycystic ovarian disease elevated circulating levels of LH 
are found (McConway et al, 1981) which are apparently the cause of the 
thecal lutéinisation responsible for the typical appearance of the 
ovaries. One of the patients, who was in the MS phase of the cycle, 
showed elevated levels of LH (Figure 3.29) at a time when such eleva­
tions do not occur in normal women (Figure 3.11). In these 2 patients 
the levels of all steroid hormones measured were higher in the plasmas 
from veins draining the contralateral ovaries than in the corresponding
peripheral plasma samples. Although these patients were not clinically 
hirsute (a condition sometimes present in association with polycystic 
ovarian disease) they showed high levels of androgens in their ovarian 
venous effluents. This elevation of androgens was particular marked in 
the case of A levels in the contralateral ovarian veins especially of the
MS phase patient (Figure 3.29). These results support the hypothesis
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that in such patients the increased androgens present in the peripheral 
circulation are ovarian in origin (Van Look 1981).
(ii) Patient with Primary Infertility and Hirsutism
One patient with a history of primary infertility and hirsutism was 
sampled at laparotomy for removal of an ovarian tumour. Samples 
were obtained of peripheral and active (tumour containing) ovarian 
venous plasma and of tumour fluid. As far as could be assessed the 
patient was in the LP stage of the cycle and this was confirmed by the 
levels of hormones in the peripheral plasma (Figure 3.31). The levels of 
all steroid hormones were higher in the plasma from the vein draining 
the active ovary than in the peripheral plasma. In this patient the levels 
of OE^ and A were considerably higher in both peripheral and active 
ovarian vein plasmas than those observed in patients at the same stage of 
normal cycles (Figures 3.15 and 3.16). Determination of the hormone 
levels in the tumour fluid showed very high concentrations of the steroid 
hormones -  OE^, A, DHT and T. Presumably the elevations of OE^ 
and A observed in peripheral and active ovarian venous plasmas would 
at least in part have been due to secretion by the tumour.
The secretions of steroid hormones observed in this patient might 
explain her symptomatology. The elevated levels of androgens would 
be responsible for her hirsutism whilst the high circulating concentra­
tions of OE^ could exert a contraceptive type effect on the ovarian/ 
pituitary/hypothalamic axis and as a result might prevent normal 
ovulation and produce infertily.
VI) Hormone Levels in Samples Obtained at Hysterectomy from
Patients Who were not Cycling Normally
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(i) Patients who were taking oral contraceptive therapy
In this study peripheral and ovarian venous samples were 
obtained from three patients who had been taking combined oestrogen/ 
progestogen oral contraceptives until a few days before the operation. 
These patients were operated on day 5 of the cycle (i.e. during the 
seven days when pills were not being taken); day 14 of the cycle but who 
had stopped taking the pill for four days prior to surgery and day 24 of 
the cycle. In addition to these three patients samples were also obtained 
from a fourth patients who had been on oral contraceptives for ten years 
until four months prior to surgery. The results of the hormone levels in 
the plasma samples from the patients who had currently been taking 
contraceptive therapy offer considerable insight into the processes which 
occur at the ovarian level during steroid contraception.
In patient A.C. (Figure 3.32), sampled on day 5 of the cycle, the 
hormone profiles obtained in the peripheral and active ovarian venous 
plasmas were consistent with the EP phase of the cycle -  peripheral 
levels of steroids were basal, in the presence of elevated levels of 
gonadotrophins, especially FSH. The levels of the steroid hormones 
(OE^, A, T and DHT) in the ovarian venous effluent were much higher 
than those observed in normally cycling patients.
In A.W. (Figure 3.33) who was on day 14 of the cycle the 
hormone patterns observed were consistent with her being in the MS 
phase of the cycle. This was confirmed by the presence of a corpus 
luteum and the steroid hormone levels in the plasma from the vein drain­
ing the active ovary being highest with respect to OE^, P and A. The 
levels of steroid hormones found in the plasma from the vein draining 
the contralateral ovary were higher than those found from normally
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menstruating patients at the same stage of the cycle (RESULTS section). 
Indeed the levels of I70H P , DHT and T in the contralateral ovarian 
venous plasma were greater than those in the active ovarian venous 
plasma.
Hormone levels in patient C.E. (Figure 3.34) sampled on day 24 
of the cycle showed that ovulation had not occurred. The ovaries were 
notable for the presence of many atretic follicles, particularly in the 
‘active’ ovary. Although P levels were low, in the peripheral and in 
both the ovarian venous plasmas, samples from the vein draining the 
active ovary contained elevated levels of OE^, 170HP and A. Contra­
lateral ovarian vein levels were basal for all 6 steroid hormones.
These result might be interpreted as showing that the following 
sequence of events occurred at the ovarian levels.
(a) During the period when the ‘pill’ was not taken a normal wave of 
follicular growth occured producing growing follicles.
(b) When the contraceptive steroids were then taken, the growth of 
these follicles was arrested but they appeared to remain dormant for a 
period of time.
(c) When the ‘pill’ was not taken for any reason at around the time of 
mid-cycle at least one of these follicles was capable of further growth 
and ovulation producing a corpus luteum.
(d) When the ‘pill’ was taken throughout the period, including mid­
cycle, the follicles in which growth had been arrested, became atretic and 
the cycle was anovulatory.
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This sequence of events explains why women on the ‘pill’ do not 
experience symptoms of oestrogen lack since they are producing OE^ 
during the EP stage. This sequence of events also indicate that it is of 
paramount importance that the ‘pill’ be taken every night especially 
around the time of mid-cycle to ensure that ovulation does not occur.
These patients who were taking oral contraceptive therapy had 
elevated levels of some steriods in the contralateral ovarian veins. In 
fact, these patients resembled the two patients with polycystic ovarian 
disease described earlier with respect to contralateral ovarian vein steroid 
levels. This suggests that perhaps the small follicles showing excessive 
thecal lutéinisation in polycystic ovarian disease patients and the atretic 
follicles found in ‘pill’ patients were similar functional units.
In addition, large (> 2  cm) retention cysts were found in the 
ovaries of two of those patients A.W. and C.E. and also in patient J.H. 
who had stopped oral contraceptive therapy four months prior to 
operation after exposure for more than ten years.
Determination of the levels of steroid hormones in the fluids 
aspirated from these retention cysts showed very high levels of all six 
steroid hormones studied (Figure 3.35). The levels of these hormones in 
the cyst fluid from the patient who was four months post-oral contra­
ceptive therapy were much lower than those in the 2 current ‘pill’ 
patients. Although these retention cysts are obviously not actively 
secreting their hormones into the general circulation (otherwise the 
peripheral levels would have been considerably higher) their existence 
and steroid content may account for the elevated levels of steroid 
hormones observed in the contralateral ovarian veins of these patients. 
It is of interest that these retention cyst fluids contained the highest
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levels of androgens found in this study. Since excessive androgens have 
been linked in the female with lack of libido the presence of such cysts 
could explain why some women experience lack of libido as a side effect 
of oral contraceptive therapy.
Whist it must be remembered that these patients attended for 
surgery for gynaecological complaints and may not therefore, be entirely 
normal ‘pill’ patients these results give some insight into the mechanism 
of action of the ‘pill’.
(ii) Early Pregnancy
In the one patient who presented for hysterectomy six weeks 
pregnant, plasma samples were obtained from the vein draining the 
ovary containing the corpus luteum and the peripheral vein. In this 
patient (Figure 3.36) high levels of HCG/LH, OE^,P, and 170HP were 
measured in peripheral and ovarian venous plasmas, confirming that at 
this stage of pregnancy the ovary is very active. The levels of hormones 
at the ovarian level were at least as high as those observed during the 
MS stage of the cycle. This finding adds further support to the well- 
established concept that early human pregnancy is maintained by the 
secretions of the corpus luteum (Csapo, Pulkinnen and Kaihola 1974).
(iii) Post-Menopausal Patients
Samples were obtained from two post-menopausal patients. One 
patient presented for hysterectomy for post-menopausal bleeding and 
had typical small atrophic ovaries. Peripheral and ovarian vein 
hormone levels in this patient (Figure 3.37) showed elevated gonadotro­
phin levels and very low levels of all six steroid hormones. The levels 
of the steroids in the ovarian venous plasma sample being less than the
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corresponding peripheral plasma levels for all hormones.
The second post-menopausal subject who presented for surgery 
because of an abdominal swelling, was found to have one small white, 
streaky, typically atrophic, post-menopausal ovary while the other ovary 
contained a 60 cm benign mucous cyst. Hormone levels were deter­
mined in peripheral plasma and plasma from a vein draining the ovary 
containing the large cyst (Figure 3.38). As in the first post-menopausal 
patient gonadotrophin levels were very high. The peripheral plasma 
steroid levels were low and consistent with menopausal levels (Barlow et 
al 1981) but in some cases were higher than those observed in the first 
patient. The levels of all six steroid hormones in contrast to the situa­
tion in the first menopausal patient were higher in the ovarian venous 
plasma than in the peripheral sample, suggesting that, although benign, 
this cyst may have been responsible for a small amount of steroid 
biosynthesis.
Since there is great variability amongst post-menopausal patients 
with regard to the incidence of post-menopausal symptoms and this can 
be related to circulating OE^ levels (Coutts 1976) it is of interest that the 
presence of such ovarian growth could alleviate an oestrogen lack.
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CONCLUSIONS
The work presented in this thesis has led to the following conclu­
sions.
(1) Specific, sensitive, accurate and precise radioimmunoassays have 
been developed for A, DHT and T. The assay for A was performed 
without chromatography, whilst the methods for DHT and T utilised 
chromatographic separation of the two steroids prior to separate deter­
minations.
(2) Using these assays profiles of the three 019 androgens have been 
determined in serial daily peripheral plasma samples throughout the 
normal human menstrual cycle.
(3) Blood samples were obtained in patients at hysterectomy from a 
peripheral vein and where possible veins draining both ovaries. Sam­
ples were obtained (bilaterally where possible) from 54 patients of whom 
42 were undergoing surgery for conditions which did not affect their 
reproductive functions. In 40 of these “normally cycling” patients, the 
stage of the menstrual cycle was accurately assessed by reference to, 
ovarian and endometrial histology, menstrual history, and peripheral 
plasma hormone levels. In all patients if possible the active ovary was 
diagnosed by visualisation and by ovarian histology. From the 40 
normally cycling women, a composite menstrual cycle was constructed.
(4) The levels of LH, FSH, PRL, P, 170HP, OE^, A, DHT and T 
were assayed in all of the ovarian venous samples -  active and contrala­
teral -  and were compared and contrasted with those in the correspond­
ing peripheral plasma samples.
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(5)(a) From the results of the determinations in para (4) above on the 
samples in the composite menstrual cycle assessments have been made 
of the contribution of both ovaries to the circulating levels of these 
steroid hormones throughout the menstrual cycle.
(b ), These data show that the active ovary at all stages of the cycle is 
responsible for steroid production. The Graafian follicle produces large 
amounts of OE^ and smaller amounts of P, 170HP and the C l9 andro­
gens whereas the corpus luteum produces large quantities of P, 170HP, 
A and OE^ and lesser amounts of T and DFIT.
(c) The data also show that the contralateral ovary is not “ inactive” 
but produces small significant amounts of OE^ and the C 19 androgens.
(6) The patients in whom peripheral and ovarian venous samples 
were obtained at surgery but who did not fit the criteria of “normally 
cycling” women included patients with abnormal cycles, patients using 
oral contraceptives a pregnant patient and post-menopausal 
patients. From the levels of hormones in their ovarian and peripheral 
venous plasmas and in fluids aspirated from ovarian cystic structures, if 
present, information has been obtained which aids understanding these 
conditions.
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FUTURE WORK
(A) The results presented in this study have confirmed that the active 
ovary (containing either the Graafian follicle or the corpus luteum) 
synthesises a number of steroid hormones. It would be of interest to 
extend this study to determine;-
(i) the true ovarian secretion rate of the hormones, by attempting to 
measure ovarian blood flow.
(ii) the cellular origin of each of the hormones. This might possibly 
be performed by in vitro studies with pure, isolated cell preparations 
either by incubation or cell culture as is already being performed in a 
few centres. Another possible source of this information, in vitro might 
arise if ovarian vein samples could be obtained from ovaries containing 
tumours of only one cellular type (e.g. granulosa cell tumours, thecoma.)
(B) The result presented in this thesis also showed that the contrala­
teral ovary at certain stages of the cycle produced small amount of
steroid hormones. It would be of interest to determine whether these 
were the products of the ovarian stroma or of the crop of small growing 
follicles which have been reported to be present in the contralateral 
ovary (Govan and Black, 1981)
(C) It would also be of interest to extend these preliminary studies 
presented in this thesis of the ovarian hormonal production in patients.
(i) on oral contraceptive therapy
(ii) with polycystic ovarian disease.
(iii) who are peri/postmenopausal.
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